Description:
METHODS AND MATERIALS FOR USING ADENOVIRUS VECTORS TO IMMUNIZE MAMMALS CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Patent Application Serial No.63/407,984, filed on September 19, 2022. The disclosure of the prior application is considered part of, and is incorporated by reference in, the disclosure of this application. SEQUENCE LISTING This application contains a Sequence Listing that has been submitted electronically as an XML file named “07039-2163WO1_SL.xml.” The XML file, created on September 15, 2023, is 38000 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety. TECHNICAL FIELD This document relates to methods and materials for using adenovirus vectors to immunize mammals. For example, adenovirus vectors can be used to intranasally deliver one or more immunogens (e.g., one or more immunogens associated with a pathogen causing an infection) to cells within a mammal (e.g., a human) such that the mammal produces an effective IgG, IgA, and T cell immune response against the immunogen(s). BACKGROUND INFORMATION An infectious disease caused by a coronavirus known as COVID-19 was first reported to the World Health Organization (WHO) Country Office in China on December 31, 2019. As of June 3, 2020, approximately 612,200,000 confirmed cases of COVID-19, including 6,500,000 deaths, have been reported to the WHO (covid19.who.int/). SUMMARY This document provides methods and materials for using adenovirus vectors to immunize mammals. For example, this document provides methods and materials for using adenovirus vectors to deliver nucleic acid intranasally to cells within a mammal (e.g., a human). This document also provides methods and materials for using adenovirus vectors to induce IgG, IgA, and T cell immune responses within a mammal (e.g., a human). The adenovirus vectors may be used as a vaccination boost to a prior vaccine, in a manner that triggers IgG, IgA, and T cell immune responses within the recipient. In some cases, adenovirus vectors (e.g., single-cycle adenovirus (SC-Ad) vectors) described herein can be used as a heterologous vaccination boost to deliver nucleic acid encoding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more) immunogens intranasally in a manner that triggers IgG, IgA, and T cell immune responses within a mammal (e.g., a human) that received at least one prior vaccine (e.g., one or more prior mRNA vaccines) against the targeted pathogen. As demonstrated herein, SC-Ads engineered to express one or more immunogens derived from a coronavirus (e.g., SARS-CoV-2) can be administered intranasally to mammals (e.g., humans) who received a prior mRNA-based or DNA-based SARS-CoV-2 vaccine (e.g., a Pfizer ® vaccine such as Comirnaty ® or an AstraZeneca ® vaccine such as Vaxzevria ® ) to induce effective IgG, IgA, and T cell immune responses against the coronavirus. For example, intranasal administration of SC-Ads designed to express a SARS- CoV-2 polypeptide such as a spike polypeptide (or a fragment thereof) as a heterologous boost to a human who received a prior mRNA-based or DNA-based SARS-CoV-2 vaccine (e.g., a Pfizer ® vaccine such as Comirnaty ® or an AstraZeneca ® vaccine such as Vaxzevria ® ) can induce the human’s immune system to produce IgG antibodies that can bind to and neutralize the coronavirus target, to produce IgA antibodies that can bind to and neutralize the coronavirus target, and/or Th1 T cell immune responses targeted against the coronavirus target. Having the ability to perform heterologous vaccination boosts produce immune responses effectively against viral and/or bacterial pathogens (e.g., a coronavirus) in mammals (e.g., humans) can improve survival and minimize the impact of the infection. Adenovirus vectors encoding one or more immunogens can be used to provide a mammal with sustained, long-term immunity against an infectious pathogen (e.g., a coronavirus). For example, adenovirus vectors encoding one or more immunogens associated with COVID-19 (e.g., one or more immunogens derived from SARS-CoV-2) can be used as a robust heterologous vaccination boost in the COVID-19 pandemic to generate humoral immunity against infections. In general, one aspect of this document features methods for providing a human who received a prior coronavirus vaccine with a heterologous vaccination boost. The methods can include, or consist essentially of, intranasally administering a SC-Ad to a human, where the SC-Ad includes a genome lacking at least a portion of a nucleic acid sequence that encodes an adenovirus polypeptide, where the SC-Ad includes the adenovirus polypeptide, where the SC-Ad includes a nucleic acid sequence encoding an immunogen of a coronavirus, and where the prior coronavirus vaccine did not comprise the SC-Ad. This aspect of the invention also provides a SC-Ad comprising a genome lacking at least a portion of a nucleic acid sequence that encodes an adenovirus polypeptide, where the SC-Ad includes the adenovirus polypeptide, and where the SC-Ad includes a nucleic acid sequence encoding an immunogen of a coronavirus, for use in a method of providing a human, who received a prior coronavirus vaccine that did not comprise the SC-Ad, with a heterologous vaccination boost, the method comprising intranasally administering the SC-Ad to the human. The adenovirus polypeptide can be a fiber polypeptide, a V polypeptide, a hexon polypeptide, a penton base polypeptide, or a pIIIa polypeptide. The immunogen can include a coronavirus Spike polypeptide or an immunogenic fragment thereof. The immunogen can consist of or consist essentially of an amino acid sequence set forth in any one of SEQ ID NOs:1-4 of International PCT Patent Publication No. WO 2022/040204. The immunogen can consist of or consist essentially of an amino acid sequence set forth in any one of SEQ ID NOs: 12, 42, 43, 44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204. The SC- Ad also can include a nucleic acid sequence encoding an adjuvant polypeptide. The adjuvant polypeptide can be a granulocyte-macrophage colony-stimulating factor (GM-CSF) polypeptide, an interleukin 4 (IL-4) polypeptide, an interleukin 21 (IL-21) polypeptide, a CD40 ligand (CD40L) polypeptide, a 4-1BB ligand (4-1BBL) polypeptide, a transforming growth factor beta (TGF-β) polypeptide, a Clostridium difficile TcdA polypeptide, a C. difficile TcdB polypeptide, or biologically active fragments thereof. The coronavirus Spike polypeptide can be fused to the adjuvant polypeptide. The coronavirus Spike polypeptide fused to the adjuvant polypeptide can consist essentially of or consist of an amino acid sequence set forth in SEQ ID NO:5 of International PCT Patent Publication No. WO 2022/040204. The SC-Ad also can include a nucleic acid sequence encoding a chaff polypeptide. The chaff polypeptide can be a fragment of an ACE2 polypeptide. The fragment of an ACE2 polypeptide can include the extracellular region of an ACE2 polypeptide and can lack a transmembrane domain. The chaff polypeptide can consist essentially of or consist of an amino acid sequence set forth in SEQ ID NO:8 of International PCT Patent Publication No. WO 2022/040204 or SEQ ID NO:9 of International PCT Patent Publication No. WO 2022/040204. The coronavirus Spike polypeptide can be fused to the chaff polypeptide. The coronavirus can be a betacoronavirus. The betacoronavirus can be SARS-CoV-2. The human can be a human who received the prior coronavirus vaccine at least 90 days before the intranasally administering. The human can be a human who received the prior coronavirus vaccine at least 120 days before the intranasally administering. The human can be a human who received the prior coronavirus vaccine at least 150 days before the intranasally administering. The human can be a human who received the prior coronavirus vaccine at least 180 days before the intranasally administering. The prior coronavirus vaccine can have been an mRNA-based vaccine. The SC-Ad can infect a cell of the human, and expression of the immunogen in the cell can lead to an increase in the amount of serum IgG antibodies that bind to the immunogen. The SC-Ad can infect a cell of the human, and expression of the immunogen in the cell can lead to an increase in the amount of mucosal IgA antibodies that bind to the immunogen. The SC-Ad can infect a cell of the human, and expression of the immunogen in the cell can lead to an increase in the amount of neutralizing antibodies in the human that bind to the immunogen. The SC-Ad can infect a cell of the human, and expression of the immunogen in the cell can lead to an increase in the number of Th1 T cells within the human that target the immunogen. In another aspect, this document features methods for providing a human who received a prior vaccine against a virus causing respiratory disease with a vaccination boost, where the method comprises intranasally administering a SC-Ad to the human, where the SC-Ad comprises a genome lacking at least a portion of a nucleic acid sequence that encodes an adenovirus polypeptide, where the SC-Ad comprises the adenovirus polypeptide, and where the SC-Ad comprises a nucleic acid sequence encoding an immunogen of the virus causing respiratory disease. This aspect of the invention also provides a SC-Ad comprising a genome lacking at least a portion of a nucleic acid sequence that encodes an adenovirus polypeptide, where the SC-Ad comprises the adenovirus polypeptide, and where the SC-Ad comprises a nucleic acid sequence encoding an immunogen of a virus causing respiratory disease, for use in a method of providing a human who received a prior vaccine against the virus causing respiratory disease with a vaccination boost, where the method comprises intranasally administering the SC-Ad to the human. Except for where context requires otherwise, a SC-Ad for use in such methods or medical uses may be substantially or entirely as described in connection with the other aspects of the invention, or any embodiment thereof. The benefits of such methods and medical uses may be as described elsewhere in the present disclosure. The virus causing the respiratory disease can be a coronavirus; an influenza virus; a respiratory syncytial virus (RSV); a metapneumovirus (MPV); a rhinovirus; a bocavirus; or a parainfluenza virus (PIV). The immunogen of the virus causing the respiratory disease can be a coronavirus Spike polypeptide or an immunogenic fragment thereof; an influenza haemagglutinin polypeptide; or an immunogenic fragment thereof; an RSV fusion (F) protein polypeptide, or an immunogenic fragment thereof; an MPV fusion (F) protein polypeptide, or an immunogenic fragment thereof; rhinovirus VP1 protein polypeptide, or an immunogenic fragment thereof; or a PIV fusion (F) protein polypeptide, or an immunogenic fragment thereof. The immunogen can include a coronavirus Spike polypeptide or an immunogenic fragment thereof. The immunogen can consist of or consist essentially of an amino acid sequence set forth in any one of SEQ ID NOs:1-4 of International PCT Patent Publication No. WO 2022/040204. The immunogen can consist of or consist essentially of an amino acid sequence set forth in any one of SEQ ID NOs: 12, 42, 43, 44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204. The SC- Ad can include a nucleic acid sequence encoding an adjuvant polypeptide. The adjuvant polypeptide can be a GM-CSF polypeptide, an IL-4 polypeptide, an IL-21 polypeptide, a CD40L polypeptide, a 4-1BBL polypeptide, a TGF-β polypeptide, a Clostridium difficile TcdA polypeptide, a C. difficile TcdB polypeptide, or biologically active fragments thereof. The immunogen can be fused to the adjuvant polypeptide. The immunogen fused to the adjuvant polypeptide can consist essentially of or consist of an amino acid sequence set forth in SEQ ID NO:5 of International PCT Patent Publication No. WO 2022/040204. The SC-Ad further can include a nucleic acid sequence encoding a chaff polypeptide. The chaff polypeptide can be a fragment of an ACE2 polypeptide. The fragment of an ACE2 polypeptide can include the extracellular region of an ACE2 polypeptide and can lack a transmembrane domain. The chaff polypeptide can consist essentially of or consist of an amino acid sequence set forth in SEQ ID NO:8 of International PCT Patent Publication No. WO 2022/040204 or SEQ ID NO:9 of International PCT Patent Publication No. WO 2022/040204. The immunogen can be fused to the chaff polypeptide. The human can be a human who received the prior coronavirus vaccine at least 90 days before the intranasally administering. The human can be a human who received the prior coronavirus vaccine at least 120 days before the intranasally administering. The human can be a human who received the prior coronavirus vaccine at least 150 days before the intranasally administering. The human can be a human who received the prior coronavirus vaccine at least 180 days before the intranasally administering. The prior vaccine can have been an mRNA-based vaccine. The SC-Ad can infect a cell of the human, and expression of the immunogen in the cell can lead to an increase in the amount of serum IgG antibodies that bind to the immunogen. The SC-Ad can infect a cell of the human, and expression of the immunogen in the cell can lead to an increase in the amount of mucosal IgA antibodies that bind to the immunogen. The SC-Ad can infect a cell of the human, and expression of the immunogen in the cell can lead to an increase in the amount of neutralizing antibodies in the human that bind to the immunogen. The SC-Ad can infect a cell of the human, and expression of the immunogen in the cell can lead to an increase in the number of Th1 T cells within the human that target the immunogen. In another aspect, this document features methods for providing a mammal who received a prior vaccine targeting a pathogen with a vaccination boost against the pathogen, where the method comprises intranasally administering a SC-Ad to the mammal, where the SC-Ad comprises a genome lacking at least a portion of a nucleic acid sequence that encodes an adenovirus polypeptide, where the SC-Ad comprises the adenovirus polypeptide, where the SC-Ad comprises a nucleic acid sequence encoding an immunogen of the pathogen. This aspect of the invention also provides a SC-Ad comprising a genome lacking at least a portion of a nucleic acid sequence that encodes an adenovirus polypeptide, where the SC-Ad comprises the adenovirus polypeptide, where the SC-Ad comprises a nucleic acid sequence encoding an immunogen of a pathogen, for use in a method of providing a mammal who received a prior vaccine targeting a pathogen with a vaccination boost against the pathogen. Except for where context requires otherwise, a SC-Ad for use in this aspect of the invention may be substantially or entirely as described in connection with the other aspects of the invention, or any embodiment thereof. The benefits of such methods and medical uses may be as described elsewhere in the present disclosure. The mammal can be a human. The pathogen can cause a respiratory disease. The pathogen causing the respiratory disease can be a coronavirus; an influenza virus; a RSV; a MPV; a rhinovirus; a bocavirus; or a PIV. The adenovirus polypeptide can be a fiber polypeptide, a V polypeptide, a hexon polypeptide, a penton base polypeptide, or a pIIIa polypeptide. The mammal can be a mammal that received the prior vaccine at least 90 days before the intranasally administering. The mammal can be a mammal that received the prior vaccine at least 120 days before the intranasally administering. The mammal can be a mammal that received the prior vaccine at least 150 days before the intranasally administering. The mammal can be a mammal that received the prior vaccine at least 180 days before the intranasally administering. The prior vaccine can have been an mRNA-based vaccine. The SC-Ad can infect a cell of the mammal, and expression of the immunogen in the cell can lead to an increase in the amount of serum IgG antibodies that bind to the immunogen. The SC-Ad can infect a cell of the mammal, and expression of the immunogen in the cell can lead to an increase in the amount of mucosal IgA antibodies that bind to the immunogen. The SC-Ad can infect a cell of the mammal, and expression of the immunogen in the cell can lead to an increase in the amount of neutralizing antibodies in the human that bind to the immunogen. The SC-Ad can infect a cell of the mammal, and expression of the immunogen in the cell can lead to an increase in the number of Th1 T cells within the mammal that target the immunogen. In another aspect, this document features methods for providing a mammal who received a prior vaccine targeting a pathogen with a heterologous vaccination boost against the pathogen. The methods can include, or consist essentially of, intranasally administering a SC-Ad to a mammal, where the SC-Ad includes a genome lacking at least a portion of a nucleic acid sequence that encodes an adenovirus polypeptide, where the SC-Ad includes the adenovirus polypeptide, where the SC-Ad includes a nucleic acid sequence encoding an immunogen of the pathogen, and where the prior vaccine did not include the SC-Ad. This aspect of the invention also provides a SC-Ad comprising a genome lacking at least a portion of a nucleic acid sequence that encodes an adenovirus polypeptide, where the SC-Ad includes the adenovirus polypeptide, where the SC-Ad includes a nucleic acid sequence encoding an immunogen of a pathogen, for use in a method of providing a mammal, who received a prior vaccine that did not include the SC-Ad, with a heterologous vaccination boost against the pathogen. The mammal can be a human. The adenovirus polypeptide can be a fiber polypeptide, a V polypeptide, a hexon polypeptide, a penton base polypeptide, or a pIIIa polypeptide. The pathogen can be a coronavirus. The coronavirus can be a betacoronavirus. The betacoronavirus can be SARS-CoV-2. The immunogen can include a coronavirus Spike polypeptide or an immunogenic fragment thereof. The mammal can be a mammal that received the prior vaccine at least 90 days before the intranasally administering. The mammal can be a mammal that received the prior vaccine at least 120 days before the intranasally administering. The mammal can be a mammal that received the prior vaccine at least 150 days before the intranasally administering. The mammal can be a mammal that received the prior vaccine at least 180 days before the intranasally administering. The prior vaccine can have been an mRNA-based vaccine. The SC-Ad can infect a cell of the mammal, and expression of the immunogen in the cell can lead to an increase in the amount of serum IgG antibodies that bind to the immunogen. The SC-Ad can infect a cell of the mammal, and expression of the immunogen in the cell can lead to an increase in the amount of mucosal IgA antibodies that bind to the immunogen. The SC-Ad can infect a cell of the mammal, and expression of the immunogen in the cell can lead to an increase in the amount of neutralizing antibodies in the human that bind to the immunogen. The SC-Ad can infect a cell of the mammal, and expression of the immunogen in the cell can lead to an increase in the number of Th1 T cells within the mammal that target the immunogen. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. DESCRIPTION OF THE DRAWINGS Figure 1 is a diagrammatic representation of dose administration and follow-up assessment schema. Figure 2 is a table providing the human subject number and number of days since the indicated final COVID-19 vaccination prior to the intranasal administration of a heterologous SC-Ad6-1 boost. Figure 3 is a bar graph plotting the fold increase over previous COVID-19 vaccine baseline of anti-coronavirus spike protein IgG antibodies detected in serum from humans on the indicated days following an intranasal administration of a heterologous SC-Ad6-1 boost. Strong anti-spike IgG immune responses induced by the intranasal heterologous boost were detected. Figure 4 is a bar graph plotting the fold increase of anti-coronavirus spike protein IgA antibodies detected in nasal mucosal secretions from humans on the indicated days following an intranasal administration of a heterologous SC-Ad6-1 boost. Strong anti-spike IgA immune responses induced by the intranasal heterologous boost were detected. Figure 5 is a bar graph plotting the fold increase of live SARS-CoV-2 neutralization by antibodies in serum from humans on the indicated days following an intranasal administration of a heterologous SC-Ad6-1 boost. Strong anti-SARS-CoV-2 neutralizing immune responses induced by the intranasal heterologous boost were detected. Figure 6 is a bar graph plotting the spot forming units (SFUs) per million peripheral blood mononuclear cells (PBMCs) for IFN-γ from humans on the indicated days following an intranasal administration of a heterologous SC-Ad6-1 boost. The T cell immune responses were strongly skewed to Th1 (critical for pathogen immunity) which was induced by the intranasal heterologous boost. Figure 7 is a bar graph plotting SFUs per million PBMCs for IL-5 from humans on the indicated days following an intranasal administration of a heterologous SC-Ad6-1 boost. The T cell immune responses were skewed toward Th1 (IFN-γ), not Th2 (IL-5), which was induced by the intranasal heterologous boost were detected. Figure 8 is a schematic of genomic map of SC-Ad6-1. DETAILED DESCRIPTION This document provides methods and materials for using adenovirus vectors to immunize mammals. In some cases, adenovirus vectors provided herein can be used to deliver intranasally nucleic acid encoding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more) immunogens to a mammal (e.g., a human) such that the mammal produces effective immune responses (e.g., IgG, IgA, and T cell immune responses) against those immunogen(s). In some embodiments, the adenovirus vectors can be used to provide a vaccination boost. For example, adenovirus vectors (e.g., single-cycle adenovirus (SC-Ad) vectors) described herein can be used as a heterologous boost to deliver nucleic acid encoding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more) immunogens intranasally in a manner that triggers IgG, IgA, and T cell immune responses within a mammal (e.g., a human) that received at least one prior vaccine (e.g., one or more prior mRNA-based and/or DNA-based vaccines) against the targeted pathogen. Except for where the context requires otherwise, the adenovirus vectors described herein may be used in any of the aspects of the present invention. An adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can be derived from any adenovirus. An adenovirus used to create an adenovirus vector provided herein can be any appropriate serotype (e.g., Ad1-Ad57). In some cases, an adenovirus can be a replication competent adenovirus. In some cases, an adenovirus can be a replication defective adenovirus. In some cases, an adenovirus can be capable of infecting a human cell (e.g., can be a human adenovirus). In some cases, an adenovirus can be capable of infection a non-human cell (e.g., can be a non-human adenovirus) such as a chimpanzee cell. Examples of adenoviruses that can be used to make an adenovirus vector provided herein include, without limitation, Ad5 adenoviruses, Ad6 adenoviruses, ChAdOx1, and ChAdOx2. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can be a SC-Ad. A SC-Ad can have a genome which lacks all or a portion of at least of one of the following adenovirus nucleic acid sequences: fiber protein-encoding sequence, V protein-encoding sequence, hexon-encoding sequence, penton base-encoding sequence (also referred to as a pIII-encoding sequence), VA RNA- encoding sequence, pIIIa protein-encoding sequence (also referred to as a minor capsid protein-encoding sequence), or other early or late gene product-encoding sequences. Examples of nucleic acid sequences that encode adenoviral polypeptides include, without limitation, those set forth in GenBank gi numbers 209842, 58478, or 2935210, and/or annotated in GenBank accession numbers M73260, X17016, or AF030154. In some cases, a deletion of all or a portion of the nucleic acid encoding one or more of the following polypeptides can be engineered into a nucleic acid encoding an adenovirus such that the adenovirus vector does not encode that full-length adenovirus polypeptide or a fully functional version of that adenovirus polypeptide: fiber protein-encoding sequence, V protein-encoding sequence, hexon-encoding sequence, penton base-encoding sequence, VA RNA-encoding sequence, pIIIa protein-encoding sequence, or other early or late gene product-encoding sequences. Such deletions can be any length that results in the deletion of one or more encoded amino acids and in a reduction or elimination of the normal function of that polypeptide. For example, portions of a nucleic acid sequence of an adenovirus can be removed such that the otherwise encoded polypeptide lacks 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, or more amino acid residues and lacks its normal activity. The portion or portions to be deleted can be removed from any location along the length of the sequence. For example, a portion of an adenovirus nucleic acid sequence can be removed at the 5’ end, the 3’ end, or an internal region of an adenovirus nucleic acid such as a fiber protein-encoding sequence, V protein-encoding sequence, hexon-encoding sequence, penton base-encoding sequence, VA RNA-encoding sequence, pIIIa protein-encoding sequence, or other early or late gene product-encoding sequences. In some cases, a SC-Ad can be as described elsewhere (see, e.g., Matchett et al., J. Virol., 93(10):e02016-18 (2019); International PCT Patent Application Publication No. WO 2009/111738; or International PCT Patent Application Publication No. WO 2022/040204). An adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can include a nucleic acid sequence encoding any appropriate immunogen (e.g., a nucleic acid that drives expression of any appropriate immunogen). In some cases, an immunogen can be an antigen. An immunogen can be a full-length immunogenic polypeptide or a portion thereof (e.g., can be derived from an immunogenic polypeptide). When an immunogenic polypeptide is from a pathogen, the immunogenic polypeptide can be from any type of pathogen (e.g., a virus, a bacterium, a protozoan, a prion, a viroid, or a fungus). In some cases, an immunogenic polypeptide can be a polypeptide expressed by a virus (e.g., a viral polypeptide). For example, an immunogenic polypeptide can be a polypeptide expressed by a coronavirus (e.g., a beta-coronavirus). Examples of viruses that can express an immunogenic polypeptide include, without limitation, SARS-CoV, HCoV NL63, HKU1, MERS-CoV, SARS-CoV-2, HIV-1, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, influenza, Ebola virus, Chiningunya virus, Zika virus, cytomegalovirus, West Nile virus, respiratory syncytial virus (RSV), metapneumovirus (MPV), a rhinovirus, a bocavirus, parainfluenza virus (PIV), and those described in Table 3-1 of “Learning from SARS: Preparing for the Next Disease Outbreak: Workshop Summary.” Institute of Medicine (US) Forum on Microbial Threats; Knobler S, Mahmoud A, Lemon S, et al., editors. Washington (DC): National Academies Press (US); 2004. In some cases, an immunogen can be derived from a polypeptide expressed by a bacterium (e.g., a bacterial polypeptide). Examples of bacteria that express polypeptides from which an immunogen can be derived include, without limitation, Clostridium (e.g., C. difficile), Staphylococcus aureus (e.g. methicillin-resistant S. aureus), Campylobacter (e.g. Campylobacter jejuni), Mycobacteria (e.g. M. tuberculosis), and Borrelia (B. burgdorferi). Examples of immunogenic polypeptides that can be expressed by a pathogen include, without limitation, C. difficile Toxin A (TcdA) polypeptides, C. difficile Toxin B (TcdB) polypeptides, coronavirus Spike polypeptides, the amino acid sequence set forth in SEQ ID NO:1 of International PCT Patent Publication No. WO 2022/040204, coronavirus nucleoproteins, coronavirus membrane proteins, coronavirus envelope proteins, coronavirus non-structural proteins (e.g., coronavirus non-structural proteins 1-16), influenza haemagglutinin polypeptides, RSV fusion (F) protein polypeptides, MPV F protein polypeptides, rhinovirus VP1 protein polypeptides, and PIV F protein polypeptides. For example, an immunogenic polypeptide associated with a pathogen can have, or can be encoded by, a sequence set forth in, for example, National Center for Biotechnology Information (NCBI) Accession Nos: MN938384 and AY772062. When an immunogenic polypeptide is from an allergen, the immunogenic polypeptide can be from any type of allergen (e.g., a substance capable of triggering an immune response that results in an allergic reaction). Examples of allergens that can express and/or shed an immunogenic polypeptide include, without limitation, Fel d 7, Can f1, beta- lactoglobulin, prolamin, parvalbumin, gliadin, Fel d1, chitinase, glutenin, cupin, prolamin, profilins, polcalcins, bet v-1-related proteins, 2S albumins, vicilins, legumins, nsLTPs, and Aed a 2. For example, adenovirus vectors encoding one or more immunogens described herein can be used to deliver intranasally immunogens to a mammal (e.g., a human) such that the mammal produces antibodies (e.g., IgG and IgA antibodies) against an allergen associated with those immunogens. For example, nucleic acid molecules that can encode an adenovirus vector encoding one or more immunogens can be used to deliver intranasally immunogens to a mammal (e.g., a human) such that the mammal produces antibodies (e.g., IgG and IgA antibodies) against an allergen associated with those immunogens. For example, an immunogenic polypeptide associated with an allergen can have, or can be encoded by, a sequence set forth in, for example, NCBI Accession Nos: NP_001363134.1, AAD56719, NP_001363136.1, NP_001363139.1, P27762.1, P10414.2, P15494.2, P43176.2, NP_001191706.1, NP_001003190.1, XP_030099003.1, or XP_001657779.1. When an immunogenic polypeptide is from a cancer cell (e.g., a cancer cell within a mammal having cancer), the immunogenic polypeptide can be expressed by any cancer cell. For example, an immunogenic polypeptide expressed by a cancer cell can be a tumor antigen. In some cases, an immunogenic polypeptide expressed by a cancer cell can be a cell surface tumor antigen. In some cases, an immunogenic polypeptide expressed by a cancer cell can be a tumor-associated antigen (TAA; e.g., an antigen, such as an abnormal protein, present on tumor cells). In some cases, an immunogenic polypeptide can be a tumor-specific antigen (TSA; e.g., an antigen present only on tumor cells). Examples of immunogenic polypeptides that can be expressed by a cancer cell and used as described herein include, without limitation, folate receptor alpha, mucin 1 (MUC-1), human epidermal growth factor receptor 2 (HER-2), estrogen receptor (ER), epidermal growth factor receptor (EGFR), folate receptor alpha, mesothelin, alphafetoprotein (AFP), carcinoembryonic antigen (CEA), CA-125, epithelial tumor antigen (ETA), melanoma-associated antigen (MAGE), antigens produced by Epstein-Barr Viruses, and antigens produced by human papilloma viruses. For example, adenovirus vectors encoding one or more immunogens as described herein can be used to deliver intranasally immunogens to a mammal (e.g., a human) such that the mammal produces antibodies (IgG and IgA antibodies) against cancer cells associated with those immunogens. For example, nucleic acid molecules that can encode an adenovirus vector encoding one or more immunogens as described herein can be used to deliver intranasally immunogens to a mammal (e.g., a human) such that the mammal produces antibodies (e.g., IgG and IgA antibodies) against cancer cells associated with those immunogens. For example, an immunogenic polypeptide associated with a cancer cell can have, or can be encoded by, a sequence set forth in, for example, NCBI Accession Nos: XP_002754883.1, AAA03229.1, Q02496.2, AAD33253.1, CEQ32409.1, YP_401631.1, YP_401632.1, or QAR15051.1. When an immunogenic polypeptide is from a cancer cell (e.g., a cancer cell within a mammal having cancer), the immunogenic polypeptide can be expressed by any type of cancer cell. Examples of such cancers include, without limitation, lung cancers, breast cancers, prostate cancers, liver cancer, kidney cancers, brain cancers, B cell cancers, T cell cancers, ovarian cancers, and skin cancers. An immunogen can be a full-length immunogenic polypeptide or a portion thereof (e.g., can be derived from an immunogenic polypeptide). For example, a nucleic acid sequence encoding an immunogenic polypeptide can be modified to remove portions of nucleic acid such that the encoded polypeptide lacks any number of amino acids (e.g., 5, 10, 15, 20, 30 amino acids, or all amino acids of the immunogenic polypeptide). In some cases, portions of a nucleic acid sequence encoding an immunogenic polypeptide can be removed from anywhere along the length of the sequence. For example, portions of the nucleic acid sequence can be removed at the 5’ end, the 3’ end, or an internal region of the target nucleic acid. In some cases, an immunogen can be designed to be secreted from cells infected with the adenovirus vector encoding the immunogen. For example, a nucleic acid sequence encoding an ER retention sequence can be removed from a nucleic acid sequence encoding an immunogen (e.g., such that the encoded immunogen lacks an ER retention sequence). In some cases, an immunogen can be designed to extend from cells infected with the adenovirus vector encoding the immunogen into the extracellular space. For example, an immunogen can include an ectodomain of an immunogenic polypeptide. In some cases, an immunogen can bind (e.g., can be designed to bind) to viral receptor (e.g., an ACE2 polypeptide). For example, an immunogen can include a receptor binding domain of an immunogenic polypeptide. In some cases, an immunogen can include (e.g., can be a fusion polypeptide of) two or more immunogenic polypeptides described herein. For example, an immunogen can include a first immunogenic polypeptide and a second immunogenic polypeptide. In some cases, a first immunogenic polypeptide and a second immunogenic polypeptide can be different polypeptides. For example, an immunogen can include a tcdA polypeptide and a tcdB polypeptide (e.g., a tcdA/B fusion polypeptide). In some cases, a first immunogenic polypeptide and a second immunogenic polypeptide can be the same polypeptide. For example, an immunogen can include a tcdB polypeptide and a tcdB polypeptide (e.g., a tcdB/B fusion polypeptide). When an immunogen includes a first immunogenic polypeptide and a second immunogenic polypeptide, the first immunogenic polypeptide can be derived from a first pathogen, and the second immunogenic polypeptide can be derived from a second pathogen. The first pathogen and the second pathogen can be the same pathogen or different pathogens. When the first pathogen and the second pathogen are the same pathogen, the first immunogenic polypeptide and the second immunogenic polypeptide can be derived from the different strains of that pathogen. For example, a first immunogenic polypeptide and a second immunogenic polypeptide can be derived from different strains of the same bacterium (e.g., C. difficile). Examples of immunogens derived from immunogenic polypeptides that can be used as described herein include, without limitation, the amino acid sequence set forth in SEQ ID NO:2 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:3 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:4 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:11 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:12 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:13 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:14 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:15 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:16 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:17 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:18 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:19 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:42 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:43 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:44 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:45 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:46 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:47 of International PCT Patent Publication No. WO 2022/040204, and the amino acid sequence set forth in SEQ ID NO:48 of International PCT Patent Publication No. WO 2022/040204. In some cases, an immunogen described herein can be a variant of a wild-type immunogen. For example, a variant of a coronavirus Spike polypeptide (e.g., a SARS-CoV-2 Spike polypeptide) can comprise or consist essentially of an amino acid sequence set forth in any one of SEQ ID NOs:1-4 of International PCT Patent Publication No. WO 2022/040204 with one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more) amino acid deletions, additions, substitutions, or combinations thereof. Examples of amino acid deletions that can be present in a variant of a coronavirus Spike polypeptide (e.g., as numbered in any one of SEQ ID NOs:1-4 of International PCT Patent Publication No. WO 2022/040204) include, without limitation, a deletion of residues 69-70, a deletion of residue 144, a deletion of residues 156-157, a deletion of residues 241-243, and a deletion of residues 246-252. Examples of amino acid substitutions that can be present in a variant of a coronavirus Spike polypeptide (e.g., as numbered in any one of SEQ ID NOs:1-4 of International PCT Patent Publication No. WO 2022/040204), include, without limitation, a L5F amino acid substitution, a S13I amino acid substitution, a L18F amino acid substitution, a T19R amino acid substitution, a T20N amino acid substitution, a P26S amino acid substitution, a G75I amino acid substitution, a A67V amino acid substitution, a V70F amino acid substitution, a T76I amino acid substitution, a D80A amino acid substitution, a D80G amino acid substitution, a T95I amino acid substitution, a D138Y amino acid substitution, a G142D amino acid substitution, a W152C amino acid substitution, a E154K amino acid substitution, a F157S amino acid substitution, a R158G amino acid substitution, a R190S amino acid substitution, a D215G amino acid substitution, a A222V amino acid substitution, a D253G amino acid substitution, a W258L amino acid substitution, a K417N amino acid substitution, a K417T amino acid substitution, a L452R amino acid substitution, a L452Q amino acid substitution, a Y453F amino acid substitution, a S477N amino acid substitution, a T478K amino acid substitution, a E484Q amino acid substitution, a E484K amino acid substitution, a F490S amino acid substitution, a E484K amino acid substitution, a S494P amino acid substitution, a N501Y amino acid substitution, a A570D amino acid substitution, a D614G amino acid substitution, a H655Y amino acid substitution, a Q677H amino acid substitution, a P681H amino acid substitution, a P681R amino acid substitution, a A701V amino acid substitution, a T716I amino acid substitution, a T859N amino acid substitution, a F888L amino substitution, a D950N amino acid substitution, a Q957R amino acid substitution, a S982A amino acid substitution, a K986P amino acid substitution, a V987P amino acid substitution, a T1027I amino acid substitution, a Q1071H amino acid substitution, a D1118H amino acid substitution, and a K1191N amino acid substitution. For example, a variant of a coronavirus Spike polypeptide can include a K986P amino acid substitution and a V987P amino acid substitution (e.g., a PP substitution). In some cases, a variant of a coronavirus Spike polypeptide can be a gamma mink variant of a coronavirus Spike polypeptide. In some cases, a variant of a coronavirus Spike polypeptide can be a delta variant of a coronavirus Spike polypeptide. In some cases, a variant of a coronavirus Spike polypeptide can be a lambda variant of a coronavirus Spike polypeptide. In some cases, a variant of a coronavirus Spike polypeptide can be an epsilon variant of a coronavirus Spike polypeptide. In some cases, a variant of a coronavirus Spike polypeptide can be a delta plus variant of a coronavirus Spike polypeptide. In some cases, an immunogen described herein can have an amino acid sequence with at least 85% sequence identity (e.g., at least 88% sequence identity, at least 90% sequence identity, at least 93% sequence identity, at least 95% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity) to the amino acid sequence set forth in any one of SEQ ID NOs:1-4 of International PCT Patent Publication No. WO 2022/040204. The percent sequence identity between a particular amino acid sequence and a sequence referenced by a particular sequence identification number is determined as follows. First, an amino acid sequence is compared to the sequence set forth in a particular sequence identification number using the BLAST 2 Sequences (Bl2seq) program from the stand-alone version of BLASTZ containing BLASTN version 2.0.14 and BLASTP version 2.0.14. This stand-alone version of BLASTZ can be obtained online at fr.com/blast or at ncbi.nlm.nih.gov. Instructions explaining how to use the Bl2seq program can be found in the readme file accompanying BLASTZ. Bl2seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. To compare two nucleic acid sequences, the options are set as follows: -i is set to a file containing the first nucleic acid sequence to be compared (e.g., C:\seq1.txt); -j is set to a file containing the second nucleic acid sequence to be compared (e.g., C:\seq2.txt); -p is set to blastn; -o is set to any desired file name (e.g., C:\output.txt); -q is set to -1; -r is set to 2; and all other options are left at their default setting. For example, the following command can be used to generate an output file containing a comparison between two sequences: C:\Bl2seq -i c:\seq1.txt -j c:\seq2.txt -p blastn -o c:\output.txt -q -1 -r 2. To compare two amino acid sequences, the options of Bl2seq are set as follows: -i is set to a file containing the first amino acid sequence to be compared (e.g., C:\seq1.txt); -j is set to a file containing the second amino acid sequence to be compared (e.g., C:\seq2.txt); -p is set to blastp; -o is set to any desired file name (e.g., C:\output.txt); and all other options are left at their default setting. For example, the following command can be used to generate an output file containing a comparison between two amino acid sequences: C:\Bl2seq -i c:\seq1.txt -j c:\seq2.txt -p blastp -o c:\output.txt. If the two compared sequences share homology, then the designated output file will present those regions of homology as aligned sequences. If the two compared sequences do not share homology, then the designated output file will not present aligned sequences. Once aligned, the number of matches is determined by counting the number of positions where an identical nucleotide or amino acid residue is presented in both sequences. A matched position refers to a position in which identical amino acid occur at the same position in aligned sequences. The percent sequence identity is determined by dividing the number of matches by the length of the sequence set forth in the identified sequence (e.g., SEQ ID NO:1 of International PCT Patent Publication No. WO 2022/040204, SEQ ID NO:2 of International PCT Patent Publication No. WO 2022/040204, SEQ ID NO:3 of International PCT Patent Publication No. WO 2022/040204, or SEQ ID NO:4 of International PCT Patent Publication No. WO 2022/040204), followed by multiplying the resulting value by 100. For example, an amino acid sequence that has 220 matches when aligned with the sequence set forth in SEQ ID NO:2 of International PCT Patent Publication No. WO 2022/040204 is 93.2 percent identical to the sequence set forth in SEQ ID NO:2 of International PCT Patent Publication No. WO 2022/040204 (i.e., 220 ÷ 236 x 100 = 93.2). It is noted that the percent sequence identity value is rounded to the nearest tenth. For example, 75.1, 75.2, 75.3, and 75.4 is rounded down to 75, while 75.5, 75.6, 75.7, 75.8, and 75.9 is rounded up to 76. It also is noted that the length value will always be an integer. In some cases, a coronavirus Spike polypeptide variant can contain the entire amino acid sequence set forth in any one of SEQ ID NOs:1-4 of International PCT Patent Publication No. WO 2022/040204, except that the amino acid sequence contains from one to ten (e.g., one to nine, two to nine, one to eight, two to eight, one to seven, one to six, one to five, one to four, one to three, two, or one) amino acid additions, deletions, substitutions, or combinations thereof, provided that the coronavirus Spike polypeptide variant has the ability to induce an immune response against a coronavirus within a mammal (e.g., a human). In some cases, a coronavirus Spike polypeptide variant can consist essentially of the amino acid sequence set forth in any one of SEQ ID NOs:1-4 of International PCT Patent Publication No. WO 2022/040204 except that the amino acid sequence contains one, two, three, four, or five amino acid residues preceding the articulated sequence of the sequence identifier (e.g., SEQ ID NO:1 of International PCT Patent Publication No. WO 2022/040204), and/or has one, two, three, four, or five amino acid residues following the articulated sequence of the sequence identifier (e.g., SEQ ID NO:1 of International PCT Patent Publication No. WO 2022/040204), provided that the coronavirus Spike polypeptide has the ability to induce an immune response against a coronavirus within a mammal (e.g., a human). In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can include nucleic acid sequence encoding two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) immunogens from different immunogenic polypeptides. For example, an adenovirus vector provided herein can include nucleic acid sequence encoding an immunogen derived from a first pathogen (e.g., an immunogen derived from an immunogenic polypeptide expressed by SARS-CoV-2) and can include nucleic acid sequence encoding an immunogen derived from a second pathogen (e.g., an immunogen derived from an immunogenic polypeptide expressed by a pathogen other than SARS-CoV-2). In some cases, an adenovirus vector provided herein that includes a nucleic acid sequence encoding two or more immunogens derived from an immunogenic polypeptide expressed by different pathogens can include nucleic acid sequence encoding a polypeptide comprising, consisting of, or consisting essentially of the amino acid sequence set forth in any one of SEQ ID NOs:1-4 of International PCT Patent Publication No. WO 2022/040204 and can include nucleic acid sequence encoding a polypeptide comprising, consisting of, or consisting essentially of the amino acid sequence set forth in any one of SEQ ID NOs:20-21 of International PCT Patent Publication No. WO 2022/040204. When an adenovirus vector provided herein includes nucleic acid sequence encoding two or more immunogens from immunogenic polypeptides expressed by different pathogens, the adenovirus vector can be used to induce an immune response against two or more pathogens. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can include nucleic acid sequence encoding two or more (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) immunogens from the same immunogenic polypeptide and/or the same pathogen. For example, an adenovirus vector provided herein can include nucleic acid sequence encoding two or more immunogens derived from the same pathogen. In some cases, an adenovirus vector provided herein that includes a nucleic acid sequence encoding two or more immunogens derived from an immunogenic polypeptide expressed by influenza can include nucleic acid sequence encoding a polypeptide comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:20 of International PCT Patent Publication No. WO 2022/040204 and can include nucleic acid sequence encoding a polypeptide comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:21 of International PCT Patent Publication No. WO 2022/040204. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) that includes a nucleic acid sequence encoding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more) immunogens also can include one or more regulatory sequences (e.g., an enhancer or a promoter sequence such as a constitutive, inducible, and/or tissue-specific promoter sequence) to drive transcription of the immunogen(s). Examples of enhancers and promoters that can be used to drive expression of a nucleic acid sequence encoding one or more immunogens of an adenovirus provided herein include, without limitation, a CMV enhancer sequence, a CMV promoter sequence, a CAG enhancer sequence, a CAG promoter sequence, a RSV enhancer sequence, a RSV promoter sequence, a Ef1alpha enhancer sequence, a Ef1alpha promoter sequence, a ubiquitin enhancer sequence, a ubiquitin promoter sequence, adenovirus enhancer sequences, and adenovirus promoter sequences. Any appropriate method can be used to detect expression of an immunogen from adenovirus vector infected cells. For example, antibodies that recognize an immunogen can be used to detect the presence or absence of the immunogen. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can include a nucleic acid sequence encoding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more) adjuvant polypeptides (e.g., nucleic acid that drives expression of one or more adjuvant polypeptides). For example, an adenovirus vector can include a nucleic acid sequence encoding one or more polypeptides that can enhance an immune response within a mammal. In some cases, an adjuvant polypeptide can be a cytokine. In some cases, an adjuvant polypeptide can be an immune stimulator. In some cases, an adjuvant polypeptide can be a toxin. In some cases, an adjuvant polypeptide can accelerate a systemic T cell response against a pathogen present within a mammal. In some cases, an adjuvant polypeptide can increase a concentration of antibodies against a pathogen at a site where the pathogen can enter a mammal’s body. For example, an adjuvant polypeptide can increase a concentration of antibodies against a virus (e.g., a coronavirus) at a mucosal site where the virus can enter a mammal’s body. Examples of adjuvant polypeptides that can be encoded by an adenovirus vectors encoding one or more immunogens described herein include, without limitation, granulocyte-macrophage colony- stimulating factor (GM-CSF) polypeptides, interleukin 4 (IL-4) polypeptides, interleukin 21 (IL-21) polypeptides, CD40 ligand (CD40L) polypeptides, 4-1BB ligand (4-1BBL) polypeptides, transforming growth factor beta (TGF-β) polypeptides, C. difficile toxin polypeptides (e.g., C. difficile TcdA polypeptides (see, e.g., SEQ ID NO:22 of International PCT Patent Publication No. WO 2022/040204), C. difficile TcdB polypeptides (see, e.g., SEQ ID NO:23 of International PCT Patent Publication No. WO 2022/040204), and/or the amino acid sequence set forth in SEQ ID NO:10 of International PCT Patent Publication No. WO 2022/040204), and influenza polypeptides (e.g., N polypeptides, H polypeptides, M polypeptides, the amino acid sequence set forth in SEQ ID NO:20 of International PCT Patent Publication No. WO 2022/040204, and/or the amino acid sequence set forth in SEQ ID NO:21 of International PCT Patent Publication No. WO 2022/040204). In some cases, an adjuvant polypeptide (e.g., SEQ ID NO:22 of International PCT Patent Publication No. WO 2022/040204) can be preceded by an AAT secretory sequence (e.g., SEQ ID NO:28 of International PCT Patent Publication No. WO 2022/040204). In some cases, a nucleic acid sequence encoding an adjuvant polypeptide (e.g., SEQ ID NO:23 of International PCT Patent Publication No. WO 2022/040204) can be preceded by a cleavage site such as a synthetic furin cleavage site (e.g., SEQ ID NO:29 of International PCT Patent Publication No. WO 2022/040204). Examples of nucleic acid sequences that can encoding an adjuvant polypeptide described herein include, without limitation, the nucleic acid sequence set forth in SEQ ID NO:24 of International PCT Patent Publication No. WO 2022/040204 and the nucleic acid sequence set forth in SEQ ID NO:25 of International PCT Patent Publication No. WO 2022/040204. In some cases, a nucleic acid sequence encoding an adjuvant polypeptide (e.g., SEQ ID NO:24 of International PCT Patent Publication No. WO 2022/040204) can be preceded by an AAT secretory sequence (e.g., SEQ ID NO:40 of International PCT Patent Publication No. WO 2022/040204). In some cases, a nucleic acid sequence encoding an adjuvant polypeptide (e.g., SEQ ID NO:25 of International PCT Patent Publication No. WO 2022/040204) can be preceded by a cleavage site such as a synthetic furin cleavage site (e.g., SEQ ID NO:41 of International PCT Patent Publication No. WO 2022/040204). An adjuvant polypeptide can be a full-length polypeptide or a fragment of an adjuvant polypeptide described herein provided that the fragment has the ability to enhance an immune response (e.g., a biologically active fragment). In some cases, an adjuvant polypeptide can be as described elsewhere (see, e.g., Matchett et al., Vaccines, 8(1):64 (2020)). In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can encode (e.g., can be designed to encode) a polypeptide that includes an immunogen fused to an adjuvant polypeptide. For example, a nucleic acid sequence encoding an immunogen can be fused to a nucleic acid sequence encoding an adjuvant polypeptide (e.g., such that the encoded immunogen is fused to the encoded adjuvant polypeptide). An example of an immunogen fused to an adjuvant polypeptide that can be encoded by an adenovirus vectors encoding one or more immunogens described herein include, without limitation, the amino acid sequence set forth in SEQ ID NO:5 of International PCT Patent Publication No. WO 2022/040204. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can include a nucleic acid sequence encoding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more) chaff polypeptides (e.g., nucleic acid that drives expression of one or more chaff polypeptides). A chaff polypeptide can be a full-length polypeptide or a fragment thereof provided that it reduces the rate of entry or inhibits entry of a pathogen into a cell within a mammal. In some cases, a chaff polypeptide can be a soluble polypeptide. For example, a soluble chaff polypeptide can be a full-length chaff polypeptide or a fragment of a chaff polypeptide that lacks a transmembrane domain. For example, a soluble chaff polypeptide can include an ectodomain of a chaff polypeptide. In some cases, a chaff polypeptide can target (e.g., target and bind to) a particular pathogen (e.g., a virus such as a coronavirus) to reduce the rate of entry or inhibit entry of the pathogen into a cell within a mammal. In some cases, a chaff polypeptide can target (e.g., target and bind to) two, three, four, five, six, or more different pathogens. In some cases, a chaff polypeptide can include one or more mutations (e.g., inactivating mutations). Examples of chaff polypeptides that can be encoded by an adenovirus vectors encoding one or more immunogens described herein include, without limitation, full-length ACE2 polypeptides and fragments thereof, full-length CD13 polypeptides and fragments thereof, full-length CEACAM1 polypeptides and fragments thereof, full-length sialydated polypeptides and fragments thereof, full-length CD46 polypeptides and fragments thereof, full-length nestin polypeptides and fragments thereof, the amino acid sequence set forth in SEQ ID NO:8 of International PCT Patent Publication No. WO 2022/040204, and the amino acid sequence set forth in SEQ ID NO:9 of International PCT Patent Publication No. WO 2022/040204. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can encode (e.g., can be designed to encode) a polypeptide that includes an immunogen fused to a chaff polypeptide. For example, a nucleic acid sequence encoding an immunogen can include a nucleic acid sequence encoding a chaff polypeptide (e.g., such that the encoded immunogen is fused to the encoded chaff polypeptide). In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can include a nucleic acid sequence encoding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more) marker polypeptides (e.g., nucleic acid that drives expression of one or more marker polypeptides). Examples of marker polypeptides that can be encoded by an adenovirus vector encoding one or more immunogens described herein include, without limitation, fluorescent polypeptides (e.g., GFP, RFP, CFP, and YFP), streptavidin polypeptides, Cre recombinase polypeptides, Cas polypeptides, luciferase polypeptides, betagalactosidase polypeptides, and sodium iodide symporter polypeptides. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can include a nucleic acid sequence encoding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more) polypeptides that can form a multimer (e.g., nucleic acid that drives expression of one or more polypeptides that can form a multimer). Examples of polypeptides that can form a multimer that can be encoded by an adenovirus vectors encoding one or more immunogens described herein include, without limitation, immunoglobulin constant region polypeptides (e.g., an Ig polypeptide), streptavidin polypeptides, and sigma coil polypeptides. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can encode (e.g., can be designed to encode) a polypeptide that includes an immunogen fused to a polypeptide that can form a multimer. For example, a nucleic acid sequence encoding an immunogen can include a nucleic acid sequence encoding a polypeptide that can form a multimer (e.g., such that the encoded immunogen is fused to the encoded polypeptide that can form a multimer). Examples of immunogens fused to a polypeptide that can form a multimer that can be encoded by an adenovirus vectors encoding one or more immunogens described herein include, without limitation, the amino acid sequence set forth in SEQ ID NO:5 of International PCT Patent Publication No. WO 2022/040204, the amino acid sequence set forth in SEQ ID NO:6 of International PCT Patent Publication No. WO 2022/040204, and the amino acid sequence set forth in SEQ ID NO:7 of International PCT Patent Publication No. WO 2022/040204. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can have a genome that is at least 85% percent identical (e.g., at least 88% sequence identical, at least 90% sequence identical, at least 93% sequence identical, at least 95% sequence identical, at least 97% sequence identical, at least 98% sequence identical, or at least 99% sequence identical) to a sequence set forth in any one of SEQ ID NOs:28-39 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:28 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:29 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:30 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:31 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:32 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:33 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:34 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:35 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:36 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:37 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:38 of International PCT Patent Publication No. WO 2022/040204. For example, an adenovirus vector provided herein can have a genome that comprising, consisting of, or consisting essentially of the nucleic acid sequence set forth in SEQ ID NO:39 of International PCT Patent Publication No. WO 2022/040204. In some cases, an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens) can have a genome that includes one or more of the coding regions set forth in any one of SEQ ID NOs:28-39 of International PCT Patent Publication No. WO 2022/040204. For example, a SC-Ad can be designed to have a genome where all the encoded polypeptides of the SC-Ad have the same amino acid sequence as those polypeptides encoded by the nucleic acid set forth in any one of SEQ ID NOs:28-39 of International PCT Patent Publication No. WO 2022/040204. In some cases, nucleic acid molecules can be designed to encode an adenovirus vector provided herein (e.g., an adenovirus vector encoding one or more immunogens such as a SC- Ad described herein). The term “nucleic acid” as used herein encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. A nucleic acid can be double-stranded or single-stranded. A single-stranded nucleic acid can be the sense strand or the antisense strand. In addition, a nucleic acid can be circular or linear. In some cases, cells (e.g., cell lines) can be designed to contain one or more adenovirus vectors described herein (e.g., one or more adenovirus vectors encoding one or more immunogens such as SC-Ads described herein). In cases where an adenovirus vector lacks all or a portion of at least of one adenovirus sequences, the cells containing the adenovirus vector can provide the missing adenovirus polypeptide. For example, when the adenovirus is designed to lack nucleic acid encoding the adenovirus fiber polypeptide, an adenovirus fiber polypeptide-expressing cell line can be used to generate the adenovirus such that the adenovirus contains the fiber polypeptide (e.g., the wild-type fiber polypeptide) while lacking the nucleic acid that encodes the fiber polypeptide (e.g., the wild-type fiber polypeptide). For example, when the adenovirus is designed to lack nucleic acid encoding the V polypeptide, an adenovirus V polypeptide-expressing cell line can be used to generate the adenovirus such that the adenovirus contains the V polypeptide (e.g., the wild-type V polypeptide) while lacking the nucleic acid that encodes the V polypeptide (e.g., the wild- type V polypeptide). For example, when the adenovirus is designed to lack nucleic acid encoding the pIIIa polypeptide, an adenovirus pIIIa polypeptide-expressing cell line can be used to generate the adenovirus such that the adenovirus contains the pIIIa polypeptide (e.g., the wild-type pIIIa polypeptide) while lacking the nucleic acid that encodes the pIIIa polypeptide (e.g., the wild-type pIIIa polypeptide). In some cases, cells containing adenovirus vectors described herein can increase the available number of copies of that virus by at least 100-fold (e.g., by 100-fold to 15,000-fold, by 500- to 10,000-fold, by 5,000- to 10,000-fold, or by 5,000- to 15,000-fold). A virus can be expanded until a desired concentration is obtained in standard cell culture media (e.g., DMEM or RPMI-1640 supplemented with 5-10% fetal bovine serum at 37°C in 5% CO 2 ). A viral titer typically is assayed by inoculating cells (e.g., A549 or 293 cells) in culture or by quantitating viral genomes by optical density or real-time PCR. In some cases, cells containing an adenovirus vector provided herein can be used to propagate the adenovirus vector (e.g., to establish a stock of the adenovirus vector). For example, a stock of the adenovirus vector can be produced by growth in mammalian cells. In some cases, a stock of the adenovirus vector can be aliquoted and frozen, and can be stored at -70°C to -80°C (e.g., at concentrations higher than the therapeutically effective dose). In some cases, a stock of the adenovirus vector can be stored in a stabilizing solution. Examples of stabilizing solutions include, without limitation, sugars (e.g., trehalose, dextrose, and glucose), amino acids, glycerol, gelatin, monosodium glutamate, Ca 2+ , and Mg 2+ . In some cases, adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens) can be formulated into a composition (e.g., a pharmaceutical composition such as a vaccine composition) for nasal administration to a mammal (e.g., a human). For example, adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens) can be formulated together with one or more pharmaceutically acceptable carriers (additives), excipients, and/or diluents for nasal administration. Examples of pharmaceutically acceptable carriers, excipients, and diluents that can be used in a composition described herein include, without limitation, sucrose, lactose, starch (e.g., starch glycolate), cellulose, cellulose derivatives (e.g., modified celluloses such as microcrystalline cellulose, and cellulose ethers like hydroxypropyl cellulose (HPC) and cellulose ether hydroxypropyl methylcellulose (HPMC)), xylitol, sorbitol, mannitol, gelatin, polymers (e.g., polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), crosslinked polyvinylpyrrolidone (crospovidone), carboxymethyl cellulose, polyethylene-polyoxypropylene-block polymers, and crosslinked sodium carboxymethyl cellulose (croscarmellose sodium)), titanium oxide, azo dyes, silica gel, fumed silica, talc, magnesium carbonate, vegetable stearin, magnesium stearate, aluminum stearate, stearic acid, antioxidants (e.g., vitamin A, vitamin E, vitamin C, retinyl palmitate, and selenium), citric acid, sodium citrate, parabens (e.g., methyl paraben and propyl paraben), petrolatum, dimethyl sulfoxide, mineral oil, serum proteins (e.g., human serum albumin), glycine, sorbic acid, potassium sorbate, water, salts or electrolytes (e.g., saline, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts), colloidal silica, magnesium trisilicate, polyacrylates, waxes, wool fat, lecithin, and corn oil. Suitable pharmaceutical formulations depend in part upon the use and the route of administration. Such forms should not prevent the composition or formulation from reaching target cells or from exerting its effect. In some cases, a composition including adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens) can include a plurality of identical adenovirus vectors that are designed to encode one or more immunogens (and/or a plurality of identical nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens). In some cases, a composition including adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens) can include a population of two or more (e.g., two, three, four, five, or more) different adenovirus vectors. For example, a composition can be designed to include two populations of adenovirus vectors, with the first population containing one or more coronavirus immunogens (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1-4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204) and the second population containing one or more adjuvant polypeptides (e.g., a GM-CSF polypeptide, an IL-4 polypeptide, an IL-21 polypeptide, a CD40L polypeptide, a 4-1BBL polypeptide, a TGF-β polypeptide, a C. difficile TcdA polypeptide, a C. difficile TcdB polypeptide, and/or biologically active fragments thereof). For example, a composition can be designed to include two populations of adenovirus vectors, with the first population containing one or more coronavirus immunogens (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1-4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204) and the second population containing a chaff polypeptide (e.g., a fragment of an ACE2 polypeptide). In some cases, a composition including adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens) can be designed to include populations of different adenovirus vectors where each population of adenovirus vectors of the composition contains a single immunogen (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding a single immunogen). For example, a composition of adenovirus vectors can be designed to include a first population of adenovirus vectors having a first coronavirus immunogen (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1-4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204) and a second population of adenovirus vectors having a second coronavirus immunogen (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1-4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204). For example, a composition of adenovirus vectors can be designed to include a first population of adenovirus vectors having a first coronavirus immunogen (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1-4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204), a second population of adenovirus vectors having a second coronavirus immunogen (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1-4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204), and a third population of adenovirus vectors having a third coronavirus immunogen (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1-4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204). In another example, a composition of adenovirus vectors can be designed to include a first population of adenovirus vectors having a first coronavirus immunogen (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1- 4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204), a second population of adenovirus vectors having a second coronavirus immunogen (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1-4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204), and a third population of adenovirus vectors an adjuvant polypeptide (e.g., a GM-CSF polypeptide, an IL-4 polypeptide, an IL-21 polypeptide, a CD40L polypeptide, a 4-1BBL polypeptide, a TGF-β polypeptide, a C. difficile TcdA polypeptide, a C. difficile TcdB polypeptide, and/or biologically active fragments thereof). In another example, a composition of adenovirus vectors can be designed to include a first population of adenovirus vectors having a first coronavirus immunogen (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1- 4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204), a second population of adenovirus vectors having a second coronavirus immunogen (e.g., an amino acid sequence set forth in any one of SEQ ID NOs:1-4, 42-44, 47, and 48 of International PCT Patent Publication No. WO 2022/040204), and a third population of adenovirus vectors having a chaff polypeptide (e.g., a fragment of an ACE2 polypeptide). This document also provides methods for using adenovirus vectors described herein (e.g., adenovirus vectors encoding one or more immunogens) and/or nucleic acid molecules that can encode an adenovirus vector described herein. In some cases, adenovirus vectors described herein and/or nucleic acid molecules that can encode an adenovirus vector described herein can be administered intranasally to a mammal (e.g., a human) as a vaccination boost to increase an immune response (e.g., to increase IgG and IgA antibody responses and/or to increase T cell responses) against a pathogen (e.g., a bacterial or a viral pathogen associated with an immunogen encoded by the adenovirus vectors). In some cases, adenovirus vectors described herein and/or nucleic acid molecules that can encode an adenovirus vector described herein can be administered intranasally to a mammal (e.g., a human) as a heterologous vaccination boost to increase an immune response (e.g., to increase IgG and IgA antibody responses and/or to increase T cell responses) against a pathogen (e.g., a bacterial or a viral pathogen associated with an immunogen encoded by the adenovirus vectors). For example, adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens) can be administered intranasally to a mammal (e.g., a human) as a heterologous vaccination boost to provide the mammal with an immune response (e.g., an IgG, IgA, and T cells immune response) effective to reduce the severity of an infection caused by a pathogen associated with the immunogen(s) encoded by the adenovirus vectors. In some cases, adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector encoding one or more immunogens) can be administered intranasally to a mammal (e.g., a human) as described herein as a heterologous vaccination boost to provide the mammal with an immune response (e.g., an IgG, IgA, and T cells immune response) effective to prevent the mammal from exhibiting symptoms of an infection caused by a pathogen associated with the immunogen(s) encoded by the adenovirus vectors. In some cases, adenovirus vectors described herein and/or nucleic acid molecules that can encode an adenovirus vector described herein can be administered intranasally to a mammal (e.g., a human) as a heterologous vaccination boost to increase IgG, IgA, and T cell immune responses within the mammal. In some cases, adenovirus vectors described herein and/or nucleic acid molecules that can encode an adenovirus vector described herein can be administered intranasally as a heterologous vaccination boost to a mammal (e.g., a human) that previously received a vaccine targeting the same pathogen (e.g., a bacterial or a viral pathogen) to increase the number of IgG and IgA antibodies (e.g., IgG and IgA antibodies against the pathogen associated with the immunogen(s) encoded by the adenovirus vectors) within the mammal. For example, adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens) can be administered intranasally as a heterologous vaccination boost to a mammal (e.g., a human) that previously received a vaccine targeting the same pathogen (e.g., a bacterial or a viral pathogen) to increase the number of IgG and IgA antibodies within the mammal by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. In some cases, adenovirus vectors described herein and/or nucleic acid molecules that can encode an adenovirus vector described herein can be administered intranasally as a heterologous vaccination boost to a mammal (e.g., a human) that previously received a vaccine targeting the same pathogen (e.g., a bacterial or a viral pathogen) to produce IgG and IgA antibodies against the immunogen(s) within the mammal starting from about 15 days post administration (or starting from about 16 days post administration, or starting from about 17 days post administration, or starting from about 18 days post administration, or starting from about 19 days post administration, or starting from about 20 days post administration, or starting from about 21 days post administration, or starting from about 22 days post administration) and lasting at least to about 40 days post administration (e.g., lasting at least to about 43 days post administration, lasting at least to about 45 days post administration, lasting at least to about 50 days post administration, lasting at least to about 55 days post administration, lasting at least to about 60 days post administration, lasting at least to about 65 days post administration, lasting at least to about 70 days post administration, lasting at least to about 75 days post administration, lasting at least to about 80 days post administration, lasting at least to about 85 days post administration, lasting at least to about 90 days post administration, lasting at least to about 95 days post administration, lasting at least to about 100 days post administration, lasting at least to about 105 days post administration, lasting at least to about 110 days post administration, lasting at least to about 115 days post administration, lasting at least to about 120 days post administration, lasting at least to about 125 days post administration, lasting at least to about 130 days post administration, or lasting at least to about 135 days post administration). The previously received vaccine can be one that the mammal (e.g., the human) received from about 21 days to about 120 months (e.g., from about 21 days to about 60 months, from about 21 days to about 36 months, from about 21 days to about 24 months, from about 21 days to about 12 months, from about 21 days to about 8 months, from about 21 days to about 6 months, from about 21 days to about 4 months, from about 21 days to about 3 months, from about 21 days to about 2 months, from about 1 month to about 120 months, from about 3 months to about 120 months, from about 6 months to about 120 months, from about 12 months to about 120 months, from about 18 months to about 120 months, from about 24 months to about 120 months, from about 36 months to about 120 months, from about 48 months to about 120 months, from about 1 month to about 60 months, from about 2 months to about 48 months, from about 3 months to about 36 months, from about 4 months to about 24 months, from about 6 months to about 18 months, from about 1 month to about 3 months, from about 3 months to about 6 months, from about 6 months to about 12 months, from about 12 months to about 24 months, from about 24 months to about 48 months, from about 36 months to about 72 months, from about 48 months to about 84 months, or from about 60 months to about 96 months) before the mammal is intranasally administered an adenovirus vector described herein (and/or nucleic acid molecules that can encode an adenovirus vector described herein). In some cases, adenovirus vectors described herein and/or nucleic acid molecules that can encode an adenovirus vector described herein can be administered intranasally as a vaccination boost to a mammal (e.g., a human) that previously received a vaccine targeting the same pathogen (e.g., a bacterial or a viral pathogen) to produce IgG and IgA antibodies against the immunogen(s) within the mammal starting from about 15 days post administration (or starting from about 16 days post administration, or starting from about 17 days post administration, or starting from about 18 days post administration, or starting from about 19 days post administration, or starting from about 20 days post administration, or starting from about 21 days post administration, or starting from about 22 days post administration) and lasting at least to about 40 days post administration (e.g., lasting at least to about 43 days post administration, lasting at least to about 45 days post administration, lasting at least to about 50 days post administration, lasting at least to about 55 days post administration, lasting at least to about 60 days post administration, lasting at least to about 65 days post administration, lasting at least to about 70 days post administration, lasting at least to about 75 days post administration, lasting at least to about 80 days post administration, lasting at least to about 85 days post administration, lasting at least to about 90 days post administration, lasting at least to about 95 days post administration, lasting at least to about 100 days post administration, lasting at least to about 105 days post administration, lasting at least to about 110 days post administration, lasting at least to about 115 days post administration, lasting at least to about 120 days post administration, lasting at least to about 125 days post administration, lasting at least to about 130 days post administration, or lasting at least to about 135 days post administration). The previously received vaccine can be one that the mammal (e.g., the human) received from about 21 days to about 120 months (e.g., from about 21 days to about 60 months, from about 21 days to about 36 months, from about 21 days to about 24 months, from about 21 days to about 12 months, from about 21 days to about 8 months, from about 21 days to about 6 months, from about 21 days to about 4 months, from about 21 days to about 3 months, from about 21 days to about 2 months, from about 1 month to about 120 months, from about 3 months to about 120 months, from about 6 months to about 120 months, from about 12 months to about 120 months, from about 18 months to about 120 months, from about 24 months to about 120 months, from about 36 months to about 120 months, from about 48 months to about 120 months, from about 1 month to about 60 months, from about 2 months to about 48 months, from about 3 months to about 36 months, from about 4 months to about 24 months, from about 6 months to about 18 months, from about 1 month to about 3 months, from about 3 months to about 6 months, from about 6 months to about 12 months, from about 12 months to about 24 months, from about 24 months to about 48 months, from about 36 months to about 72 months, from about 48 months to about 84 months, or from about 60 months to about 96 months) before the mammal is intranasally administered an adenovirus vector described herein (and/or nucleic acid molecules that can encode an adenovirus vector described herein). In some cases, adenovirus vectors described herein and/or nucleic acid molecules that can encode an adenovirus vector described herein can be administered intranasally as a heterologous vaccination boost to a mammal (e.g., a human) that previously received a vaccine targeting the same pathogen (e.g., a bacterial or a viral pathogen) to increase a T cell response within the mammal. For example, adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens) can be administered intranasally as a heterologous vaccination boost to a mammal that previously received a vaccine targeting the same pathogen (e.g., a bacterial or a viral pathogen) to increase the number of activated T cells (e.g., activated Th1 T cells) within the mammal by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. As described herein, a SC-Ad engineered to encode one or more immunogens (e.g., a coronavirus Spike polypeptide) can be intranasally administered as a heterologous vaccination boost to a mammal (e.g., a human) that previously received a vaccine targeting the same pathogen (e.g., a bacterial or a viral pathogen) to induce IgG antibodies, IgA antibodies, and/or Th1 T cell responses (e.g., skewed Th1 T cell responses) within the mammal. For example, a SC-Ad engineered to encode a SARS-CoV-2 Spike polypeptide can be intranasally administered as a heterologous vaccination boost to a human who previously received an mRNA-based or DNA-based SARS-CoV-2 vaccine (e.g., a Pfizer ® vaccine such as Comirnaty ® , an AstraZeneca ® vaccine such as Vaxzevria ® , a Moderna ® vaccine such as Spikevax ® , a Novavax ® vaccine such as Nuvaxovid ® , and/or Sputnik) to induce IgG antibodies, IgA antibodies, and/or Th1 T cell responses against coronaviruses within the human. The previously received SARS-CoV-2 vaccine can be one that the human received from about 21 days to about 120 months (e.g., e.g., from about 21 days to about 60 months, from about 21 days to about 36 months, from about 21 days to about 24 months, from about 21 days to about 12 months, from about 21 days to about 8 months, from about 21 days to about 6 months, from about 21 days to about 4 months, from about 21 days to about 3 months, from about 21 days to about 2 months, from about 1 month to about 120 months, from about 3 months to about 120 months, from about 6 months to about 120 months, from about 12 months to about 120 months, from about 18 months to about 120 months, from about 24 months to about 120 months, from about 36 months to about 120 months, from about 48 months to about 120 months, from about 1 month to about 60 months, from about 2 months to about 48 months, from about 3 months to about 36 months, from about 4 months to about 24 months, from about 6 months to about 18 months, from about 1 month to about 3 months, from about 3 months to about 6 months, from about 6 months to about 12 months, from about 12 months to about 24 months, from about 24 months to about 48 months, from about 36 months to about 72 months, from about 48 months to about 84 months, or from about 60 months to about 96 months) before the human is intranasally administered a SC-Ad described herein (e.g., a SC-Ad engineered to encode a SARS-CoV-2 Spike polypeptide). The previously received SARS-CoV-2 vaccine can be one that the human received at least 90 days (e.g., at least 120 days, at least 150 days before said intranasally administering, or at least 180 days) before the human is intranasally administered a SC-Ad described herein (e.g., a SC-Ad engineered to encode a SARS-CoV-2 Spike polypeptide). Adenovirus vectors described herein (e.g., adenovirus vectors encoding one or more immunogens) and/or nucleic acid molecules that can encode an adenovirus vector described herein can be administered intranasally to any appropriate mammal (e.g., to increase an immune response against a pathogen such as a bacterial or a viral pathogen associated with the immunogen(s) encoded by the adenovirus vectors within that mammal). In some cases, the mammal can be a mammal that has not had a previous infection with a pathogen associated with an immunogen encoded by an adenovirus vector provided herein. In some cases, the mammal can be a mammal that has had a previous infection with a pathogen closely related (e.g., genetically related) to a pathogen associated with an immunogen encoded by an adenovirus vector provided herein. In some cases, the mammal can be a mammal that has an infection (e.g., an ongoing infection) with a pathogen associated with an immunogen encoded by an adenovirus vector provided herein. Examples of mammals that can be intranasally administered adenovirus vectors described herein encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more immunogens) include, without limitation, humans, non-human primates such as monkeys, dogs, cats, horses, cows, pigs, sheep, mice, rats, rabbits, hamsters, bats, raccoons, and ferrets. In some cases, a human can be intranasally administered one or more adenovirus vectors described herein and/or nucleic acid molecules that can encode an adenovirus vector described herein to increase an immune response against a pathogen (e.g., a bacterial or a viral pathogen associated with an immunogen encoded by the adenovirus vectors). Adenovirus vectors described herein (e.g., adenovirus vectors encoding one or more immunogens) and/or nucleic acid molecules that can encode an adenovirus vector described herein (e.g., a composition such as a vaccine composition including adenovirus vectors provided herein and/or nucleic acid molecules that can encode an adenovirus vector provided herein) can be administered intranasally (e.g., administered intranasally as a heterologous vaccination boost) to a mammal (e.g., a human) in any appropriate amount (e.g., any appropriate dose). Effective amounts can vary depending on the age and general health condition of the subject, excipient usage, the possibility of co-usage with other therapeutic treatments such as use of other agents, and the judgment of the treating physician. An effective amount of a composition containing adenovirus vectors encoding one or more immunogens (and/or nucleic acid molecules that can encode an adenovirus vector encoding one or more immunogens) can be any amount that can induce an immune response in a mammal as described herein without producing significant toxicity to the mammal. For example, an effective amount adenovirus vectors encoding one or more immunogens can be, for example, from about 10 8 viral particles (vp) to about 10 14 vp (e.g., from about 10 8 vp to about 10 13 vp, from about 10 8 vp to about 10 12 vp, from about 10 8 vp to about 10 11 vp, from about 10 8 vp to about 10 10 vp, from about 10 8 vp to about 10 9 vp, from about 10 9 vp to about 10 14 vp, from about 10 10 vp to about 10 14 vp, from about 10 11 vp to about 10 14 vp, from about 10 12 vp to about 10 14 vp, from about 10 13 vp to about 10 14 vp, from about 10 9 vp to about 10 13 vp, from about 10 10 vp to about 10 12 vp, from about 10 9 vp to about 10 11 vp, from about 10 10 vp to about 10 12 vp, or from about 10 1 vp to about 10 13 vp). The effective amount can remain constant or can be adjusted as a sliding scale or variable dose depending on the mammal’s response to treatment. Various factors can influence the actual effective amount used for a particular application. For example, the frequency of administration and/or use of multiple treatment agents may require an increase or decrease in the actual effective amount administered. Adenovirus vectors provided herein (e.g., adenovirus vectors encoding one or more immunogens) and/or nucleic acid molecules that can encode an adenovirus vector provided herein (e.g., a composition such as a vaccine composition including adenovirus vectors provided herein and/or nucleic acid molecules that can encode an adenovirus vector provided herein) can be administered intranasally (e.g., administered intranasally as a heterologous vaccination boost) to a mammal (e.g., a human) in any appropriate frequency. The frequency of administration can be any frequency that can induce an immune response in a mammal without producing significant toxicity to the mammal. In some cases, adenovirus vectors provided herein and/or nucleic acid molecules that can encode an adenovirus vector provided herein can be administered intranasally (e.g., administered intranasally as a heterologous vaccination boost) to a mammal once (e.g., in a single administration). In some cases, adenovirus vectors provided herein and/or nucleic acid molecules that can encode an adenovirus vector provided herein can be administered intranasally (e.g., administered intranasally as a heterologous vaccination boost) to a mammal several times (e.g., as several administrations). For example, the frequency of administration can be from about once a day to about every three days, from about once a day to about once a week, from about once a week to about every 3 weeks, from about once a week to about every 6 weeks, from about once every three months to about once every 6 months, from once every 6 months to once every 18 months, or from once every 6 months to once every year. As with the effective amount, various factors can influence the actual frequency of administration used for a particular application. For example, the effective amount and/or use of multiple treatment agents may require an increase or decrease in administration frequency. In some cases, one or more adenovirus vectors provided herein (e.g., an adenovirus vector encoding one or more immunogens) and/or a nucleic acid molecule that can encode an adenovirus vector provided herein (e.g., a composition such as a vaccine composition including adenovirus vectors provided herein and/or nucleic acid molecules that can encode an adenovirus vector provided herein) can be administered intranasally (e.g., administered intranasally as a heterologous vaccination boost) to a mammal (e.g., a human) as the sole active ingredient to increase an immune response (e.g., to increase IgG and IgA antibody responses and/or to increase Th1 responses) against a pathogen (e.g., a bacterial or a viral pathogen associated with an immunogen encoded by the adenovirus vectors). For example, a composition containing adenovirus vectors described herein encoding one or more coronavirus immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more coronavirus immunogens) can be administered intranasally (e.g., administered intranasally as a heterologous vaccination boost) to a mammal (e.g., a human) as the sole active ingredient to increase an immune response (e.g., to increase IgG and IgA antibody responses and/or to increase Th1 T cell responses) against a coronavirus. In some cases, one or more adenovirus vectors provided herein (e.g., an adenovirus vector encoding one or more immunogens) and/or a nucleic acid molecule that can encode an adenovirus vector provided herein (e.g., a composition such as a vaccine composition including adenovirus vectors provided herein and/or nucleic acid molecules that can encode an adenovirus vector provided herein) can be administered intranasally (e.g., administered intranasally as a heterologous vaccination boost) to a mammal (e.g., a human) together with one or more (e.g., one, two, three, four, five or more) additional agents/therapies used to increase an immune response (e.g., to increase IgG and IgA antibody responses and/or to increase Th1 T cell responses) against a pathogen (e.g., a bacterial or a viral pathogen associated with an immunogen encoded by the adenovirus vectors). For example, a composition containing adenovirus vectors described herein encoding one or more coronavirus immunogens (and/or nucleic acid molecules that can encode an adenovirus vector described herein encoding one or more coronavirus immunogens) can be administered intranasally (e.g., administered intranasally as a heterologous vaccination boost) to a mammal (e.g., a human) together with one or more (e.g., one, two, three, four, five or more) additional agents/therapies used to increase an immune response (e.g., to increase IgG and IgA antibody responses and/or to increase Th1 T cell responses) against a coronavirus. In cases where one or more adenovirus vectors provided herein (e.g., an adenovirus vector encoding one or more immunogens) and/or a nucleic acid molecule that can encode an adenovirus vector provided herein (e.g., a composition such as a vaccine composition including adenovirus vectors provided herein and/or nucleic acid molecules that can encode an adenovirus vector provided herein) are used in combination with one or more additional agents/therapies used to increase an immune response (e.g., to increase IgG and IgA antibody responses and/or to increase Th1 T cell responses), the one or more adenovirus vectors provided herein (and/or a nucleic acid molecule that can encode an adenovirus vector provided herein) and the one or more additional agents/therapies can be administered at the same time (e.g., in a single composition) or independently. For example, one or more adenovirus vectors provided herein (and/or a nucleic acid molecule that can encode an adenovirus vector provided herein) can be administered first, and the one or more additional agents/therapies administered second, or vice versa. The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. EXAMPLES Example 1: A Replicating Single-Cycle Adenovirus Vaccine Against COVID-19 SC-Ad6-1 (a COVID-19 vaccine; Figures 8 and 9) was safe and well tolerated in the initial ascending dose cohorts. In addition, when SC-Ad6-1 was given as a heterologous boost of humans who received a previous mRNA COVID-19 vaccine, a strong mucosal and systemic neutralizing response against the SARS-CoV-2 spike protein was observed in a majority of the humans. Ten healthy volunteers who had been fully vaccinated against COVID-19 for at least 3 months prior to Day 1 of SC-Ad6-1 dosing as a heterologous vaccination boost were enrolled (Figure 2). One of the ten volunteers was removed from the analysis since that person became infected with SARS-CoV-2 two days into the study. The humans were dosed with 8.0e8 infectious units (IU) of SC-Ad6-1 via intranasal administration, and humoral and cellular immune responses were evaluated. The immunogenicity endpoints were humoral and cellular immune responses to SARS-CoV-2 as determined by (a) the presence of serum anti-SARS-CoV-2 neutralizing antibodies via a live virus assay, (b) the presence of serum IgG antibodies specific for the SARS-CoV-2 spike protein via an ELISA, (c) the presence of mucosal IgA antibodies specific for the SARS-CoV-2 spike protein via an ELISA, and (d) the presence of cytokine-producing Th1 T cells specific for the SARS-CoV-2 spike protein via or interferon-γ secretion from stimulated PBMCs. For safety reasons, the first two humans (sentinels) were dosed ahead of the remaining eight humans and at least one hour apart from each other (Figure 1). The profile of adverse events in the sentinels was reviewed 48 hours post intranasal administration (study Day 3). No safety concerns were observed in the sentinels, and the remainder of human participants were dosed at the same dose level after at least 48 hours have elapsed following dosing of the sentinel participants (Figure 1). Each human participant visited the clinical facility on the day of dosing (Day 1) and on study Days 3, 8, 22, 29, and 43 for follow-up assessments of safety, immunogenicity, and pharmacodynamics. A follow-up phone call was conducted on study Day 15 to assess adverse events. The End-of-Study (EoS) visit was on study Day 106 (Figure 1). Intranasal administration of SC-Ad6-1 as a nasal spray to humans as a heterologous vaccination boost resulted in an increase in the amount of serum IgG antibodies specific for the SARS-CoV-2 spike protein as determined by an ELISA (Figure 3), resulted in an increase in the amount of mucosal IgA antibodies specific for the SARS-CoV-2 spike protein as determined by an ELISA (Figure 4), resulted in an increase in the amount of serum anti- SARS-CoV-2 neutralizing antibodies as determined by a live virus assay (Figure 5), and resulted in T cells against SARS-CoV-2 spike being skewed towards a Th1 response (critical for pathogen immunity) versus a Th2 response as determined by interferon-γ secretion (Figure 6) versus IL-5 secretion (Figure 7) from stimulated PBMCs, respectively. These results demonstrate that a SC-Ad designed to encode a SARS-CoV-2 immunogen can be administered intranasally as a heterologous vaccination boost to humans who received a prior COVID-19 vaccine to induce IgG and IgA antibodies against SARS- CoV-2 and Th1 T cell immune responses (e.g., Th1 skewed T cell immune responses) against SARS-CoV-2. Example 2: SC-Ad6-1 DNA sequence SEQ ID NO:1 CGCCATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGG
AG TTTGTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTG
TG ATGTTGTAAGTGTGGCGGAACACATGTAAGCGCCGGATGTGGTAAAAGTGACGTTTTTGG
TG TGCGCCGGTGTACACGGGAAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAA
AT TTGGGCGTAACCAAGTAATATTTGGCCATTTTCGCGGGAAAACTGAATAAGAGGAAGTGA
AA TCTGAATAATTCTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCGCGGGGACTTTG
AC CGTTTACGTGGAGACTCGCCCAGGTGTTTTTCTCAGGTGTTTTCCGCGTTCCGGGTCAAA
GT TGGCGTTTTATTATTATAGTCAGCTGACGCGCAGTGTATTTATACCCGGTGAGTTCCTCA
AG AGGCCACTCTTGAGTGCCAGCGAGTAGAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGA
CT GAAAATGAGACATATTATCTGCCACGGAGGTGTTATTACCGAAGAAATGGCCGCCAGTCT
TT TGGACCAGCTGATCGAAGAGGTACTGGCTGATAATCTTCCACCTCCTAGCCATTTTGAAC
CA CCTACCCTTCACGAACTGTATGATTTAGACGTGACGGCCCCCGAAGATCCCAACGAGGAG
GC GGTTTCGCAGATTTTTCCCGAGTCTGTAATGTTGGCGGTGCAGGAAGGGATTGACTTATT
CA CTTTTCCGCCGGCGCCCGGTTCTCCGGAGCCGCCTCACCTTTCCCGGCAGCCCGAGCAGC
CG GAGCAGAGAGCCTTGGGTCCGGTTTCTATGCCAAACCTTGTGCCGGAGGTGATCGATCTT
AC CTGCCACGAGGCTGGCTTTCCACCCAGTGACGACGAGGATGAAGAGGGTGAGGAGTTTGT
GT TAGATTATGTGGAGCACCCCGGGCACGGTTGCAGGTCTTGTCATTATCACCGGAGGAATA
CG GGGGACCCAGATATTATGTGTTCGCTTTGCTATATGAGGACCTGTGGCATGTTTGTCTAC
AG TAAGTGAAAAATTATGGGCAGTGGGTGATAGAGTGGTGGGTTTGGTGTGGTAATTTTTTT
TT TAATTTTTACAGTTTTGTGGTTTAAAGAATTTTGTATTGTGATTTTTTAAAAGGTCCTGT
GT CTGAACCTGAGCCTGAGCCCGAGCCAGAACCGGAGCCTGCAAGACCTACCCGGCGTCCTA
AA TTGGTGCCTGCTATCCTGAGACGCCCGACATCACCTGTGTCTAGAGAATGCAATAGTAGT
AC GGATAGCTGTGACTCCGGTCCTTCTAACACACCTCCTGAGATACACCCGGTGGTCCCGCT
GT GCCCCATTAAACCAGTTGCCGTGAGAGTTGGTGGGCGTCGCCAGGCTGTGGAATGTATCG
AG GACTTGCTTAACGAGTCTGGGCAACCTTTGGACTTGAGCTGTAAACGCCCCAGGCCATAA
GG TGTAAACCTGTGATTGCGTGTGTGGTTAACGCCTTTGTTTGCTGAATGAGTTGATGTAAG
TT TAATAAAGGGTGAGATAATGTTTAACTTGCATGGCGTGTTAAATGGGGCGGGGCTTAAAG
GG TATATAATGCGCCGTGGGCTAATCTTGGTTACATCTGACCTCATGGAGGCTTGGGAGTGT
TT GGAAGATTTTTCTGCTGTGCGTAACTTGCTGGAACAGAGCTCTAACAGTACCTCTTGGTT
TT GGAGGTTTCTGTGGGGCTCCTCCCAGGCAAAGTTAGTCTGCAGAATTAAGGAGGATTACA
AG TGGGAATTTGAAGAGCTTTTGAAATCCTGTGGTGAGCTGTTTGATTCTTTGAATCTGGGT
CA CCAGGCGCTTTTCCAAGAGAAGGTCATCAAGACTTTGGATTTTTCCACACCGGGGCGCGC
TG CGGCTGCTGTTGCTTTTTTGAGTTTTATAAAGGATAAATGGAGCGAAGAAACCCATCTGA
GC GGGGGGTACCTGCTGGATTTTCTGGCCATGCATCTGTGGAGAGCGGTGGTGAGACACAAG
AA TCGCCTGCTACTGTTGTCTTCCGTCCGCCCGGCAATAATACCGACGGAGGAGCAACAGCA
GG AGGAAGCCAGGCGGCGGCGGCGGCAGGAGCAGAGCCCATGGAACCCGAGAGCCGGCCTGG
AC CCTCGGGAATGAATGTTGTACAGGTGGCTGAACTGTTTCCAGAACTGAGACGCATTTTAA
CC ATTAACGAGGATGGGCAGGGGCTAAAGGGGGTAAAGAGGGAGCGGGGGGCTTCTGAGGCT
AC AGAGGAGGCTAGGAATCTAACTTTTAGCTTAATGACCAGACACCGTCCTGAGTGTGTTAC
TT TTCAGCAGATTAAGGATAATTGCGCTAATGAGCTTGATCTGCTGGCGCAGAAGTATTCCA
TA AAGCAGCTGACCACTTACTGGCTGCAGCCAGGGGATGATTTTGAGGAGGCTATTAGGGTA
TA TGCAAAGGTGGCACTTAGGCCAGATTGCAAGTACAAGATTAGCAAACTTGTAAATATCAG
GA ATTGTTGCTACATTTCTGGGAACGGGGCCGAGGTGGAGATAGATACGGAGGATAGGGTGG
CC TTTAGATGTAGCATGATAAATATGTGGCCGGGGGTGCTTGGCATGGACGGGGTGGTTATT
AT GAATGTGAGGTTTACTGGTCCCAATTTTAGCGGTACGGTTTTCCTGGCCAATACCAATCT
TA TCCTACACGGTGTAAGCTTCTATGGGTTTAACAATACCTGTGTGGAAGCCTGGACCGATG
TA AGGGTTCGGGGCTGTGCCTTTTACTGCTGCTGGAAGGGGGTGGTGTGTCGCCCCAAAAGC
AG GGCTTCAATTAAGAAATGCCTGTTTGAAAGGTGTACCTTGGGTATCCTGTCTGAGGGTAA
CT CCAGGGTGCGCCACAATGTGGCCTCCGACTGTGGTTGCTTTATGCTAGTGAAAAGCGTGG
CT GTGATTAAGCATAACATGGTGTGTGGCAACTGCGAGGACAGGGCCTCTCAGATGCTGACC
TG CTCGGACGGCAACTGTCACTTGCTGAAGACCATTCACGTAGCCAGCCACTCTCGCAAGGC
CT GGCCAGTGTTTGAGCACAACATACTGACCCGCTGTTCCTTGCATTTGGGTAACAGGAGGG
GG GTGTTCCTACCTTACCAATGCAATTTGAGTCACACTAAGATATTGCTTGAGCCCGAGAGC
AT GTCCAAGGTGAACCTGAACGGGGTGTTTGACATGACCATGAAGATCTGGAAGGTGCTGAG
GT ACGATGAGACCCGCACCAGGTGCAGACCCTGCGAGTGTGGCGGTAAACATATTAGGAACC
AG CCTGTGATGCTGGATGTGACCGAGGAGCTGAGGCCCGATCACTTGGTGCTGGCCTGCACC
CG CGCTGAGTTTGGCTCTAGCGATGAAGATACAGATTGAGGTACTGAAATGTGTGGGCGTGG
CT TAAGGGTGGGAAAGAATATATAAGGTGGGGGTCTCATGTAGTTTTGTATCTGTTTTGCAG
CA GCCGCCGCCATGAGCGCCAACTCGTTTGATGGAAGCATTGTGAGCTCATATTTGACAACG
CG CATGCCCCCATGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATTGATGGTCGCCC
CG TCCTGCCCGCAAACTCTACTACCTTGACCTACGAGACCGTGTCTGGAACGCCGTTGGAGA
CT GCAGCCTCCGCCGCCGCTTCAGCCGCTGCAGCCACCGCCCGCGGGATTGTGACTGACTTT
GC TTTCCTGAGCCCGCTTGCAAGCAGTGCAGCTTCCCGTTCATCCGCCCGCGATGACAAGTT
GA CGGCTCTTTTGGCACAATTGGATTCTTTGACCCGGGAACTTAATGTCGTTTCTCAGCAGC
TG TTGGATCTGCGCCAGCAGGTTTCTGCCCTGAAGGCTTCCTCCCCTCCCAATGCGGTTTAA
AA CATAAATAAAAACCAGACTCTGTTTGGATTTGGATCAAGCAAGTGTCTTGCTGTCTTTAT
TT AGGGGTTTTGCGCGCGCGGTAGGCCCGGGACCAGCGGTCTCGGTCGTTGAGGGTCCTGTG
TA TTTTTTCCAGGACGTGGTAAAGGTGACTCTGGATGTTCAGATACATGGGCATAAGCCCGT
CT CTGGGGTGGAGGTAGCACCACTGCAGAGCTTCATGCTGCGGGGTGGTGTTGTAGATGATC
CA GTCGTAGCAGGAGCGCTGGGCGTGGTGCCTAAAAATGTCTTTCAGTAGCAAGCTGATTGC
CA GGGGCAGGCCCTTGGTGTAAGTGTTTACAAAGCGGTTAAGCTGGGATGGGTGCATACGTG
GG GATATGAGATGCATCTTGGACTGTATTTTTAGGTTGGCTATGTTCCCAGCCATATCCCTC
CG GGGATTCATGTTGTGCAGAACCACCAGCACAGTGTATCCGGTGCACTTGGGAAATTTGTC
AT GTAGCTTAGAAGGAAATGCGTGGAAGAACTTGGAGACGCCCTTGTGACCTCCAAGATTTT
CC ATGCATTCGTCCATAATGATGGCAATGGGCCCACGGGCGGCGGCCTGGGCGAAGATATTT
CT GGGATCACTAACGTCATAGTTGTGTTCCAGGATGAGATCGTCATAGGCCATTTTTACAAA
GC GCGGGCGGAGGGTGCCAGACTGCGGTATAATGGTTCCATCCGGCCCAGGGGCGTAGTTAC
CC TCACAGATTTGCATTTCCCACGCTTTGAGTTCAGATGGGGGGATCATGTCTACCTGCGGG
GC GATGAAGAAAACCGTTTCCGGGGTAGGGGAGATCAGCTGGGAAGAAAGCAGGTTCCTAAG
CA GCTGCGACTTACCGCAGCCGGTGGGCCCGTAAATCACACCTATTACCGGCTGCAACTGGT
AG TTAAGAGAGCTGCAGCTGCCGTCATCCCTGAGCAGGGGGGCCACTTCGTTAAGCATGTCC
CT GACTTGCATGTTTTCCCTGACCAAATCCGCCAGAAGGCGCTCGCCGCCCAGCGATAGCAG
TT CTTGCAAGGAAGCAAAGTTTTTCAACGGTTTGAGGCCGTCCGCCGTAGGCATGCTTTTGA
GC GTTTGACCAAGCAGTTCCAGGCGGTCCCACAGCTCGGTCACGTGCTCTACGGCATCTCGA
TC CAGCATATCTCCTCGTTTCGCGGGTTGGGGCGGCTTTCGCTGTACGGCAGTAGTCGGTGC
TC GTCCAGACGGGCCAGGGTCATGTCTTTCCACGGGCGCAGGGTCCTCGTCAGCGTAGTCTG
GG TCACGGTGAAGGGGTGCGCTCCGGGTTGCGCGCTGGCCAGGGTGCGCTTGAGGCTGGTCC
TG CTGGTGCTGAAGCGCTGCCGGTCTTCGCCCTGCGCGTCGGCCAGGTAGCATTTGACCATG
GT GTCATAGTCCAGCCCCTCCGCGGCGTGGCCCTTGGCGCGCAGCTTGCCCTTGGAGGAGGC
GC CGCACGAGGGGCAGTGCAGACTTTTAAGGGCGTAGAGCTTGGGCGCGAGAAATACCGATT
CC GGGGAGTAGGCATCCGCGCCGCAGGCCCCGCAGACGGTCTCGCATTCCACGAGCCAGGTG
AG CTCTGGCCGTTCGGGGTCAAAAACCAGGTTTCCCCCATGCTTTTTGATGCGTTTCTTACC
TC TGGTTTCCATGAGCCGGTGTCCACGCTCGGTGACGAAAAGGCTGTCCGTGTCCCCGTATA
CA GACTTGAGAGGCCTGTCCTCGAGCGGTGTTCCGCGGTCCTCCTCGTATAGAAACTCGGAC
CA CTCTGAGACGAAGGCTCGCGTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCG
GT CGTTGTCCACTAGGGGGTCCACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTCTTCGG
CA TCAAGGAAGGTGATTGGTTTATAGGTGTAGGCCACGTGACCGGGTGTTCCTGAAGGGGGG
CT ATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTGCGAGGGC
CA GCTGTTGGGGTGAGTACTCCCTCTCAAAAGCGGGCATGACTTCTGCGCTAAGATTGTCAG
TT TCCAAAAACGAGGAGGATTTGATATTCACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCC
GC GTCCATCTGGTCAGAAAAGACAATCTTTTTGTTGTCAAGCTTGGTGGCAAACGACCCGTA
GA GGGCGTTGGACAGCAACTTGGCGATGGAGCGCAGGGTTTGGTTTTTGTCGCGATCGGCGC
GC TCCTTGGCCGCGATGTTTAGCTGCACGTATTCGCGCGCAACGCACCGCCATTCGGGAAAG
AC GGTGGTGCGCTCGTCGGGCACTAGGTGCACGCGCCAACCGCGGTTGTGCAGGGTGACAAG
GT CAACGCTGGTGGCTACCTCTCCGCGTAGGCGCTCGTTGGTCCAGCAGAGGCGGCCGCCCT
TG CGCGAGCAGAATGGCGGTAGTGGGTCTAGCTGCGTCTCGTCCGGGGGGTCTGCGTCCACG
GT AAAGACCCCGGGCAGCAGGCGCGCGTCGAAGTAGTCTATCTTGCATCCTTGCAAGTCTAG
CG CCTGCTGCCATGCGCGGGCGGCAAGCGCGCGCTCGTATGGGTTGAGTGGGGGACCCCATG
GC ATGGGGTGGGTGAGCGCGGAGGCGTACATGCCGCAAATGTCGTAAACGTAGAGGGGCTCT
CT GAGTATTCCAAGATATGTAGGGTAGCATCTTCCACCGCGGATGCTGGCGCGCACGTAATC
GT ATAGTTCGTGCGAGGGAGCGAGGAGGTCGGGACCGAGGTTGCTACGGGCGGGCTGCTCTG
CT CGGAAGACTATCTGCCTGAAGATGGCATGTGAGTTGGATGATATGGTTGGACGCTGGAAG
AC GTTGAAGCTGGCGTCTGTGAGACCTACCGCGTCACGCACGAAGGAGGCGTAGGAGTCGCG
CA GCTTGTTGACCAGCTCGGCGGTGACCTGCACGTCTAGGGCGCAGTAGTCCAGGGTTTCCT
TG ATGATGTCATACTTATCCTGTCCCTTTTTTTTCCACAGCTCGCGGTTGAGGACAAACTCT
TC GCGGTCTTTCCAGTACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGGTAAGAGCCTAN
CA TGTAGAACTGGTTGACGGCCTGGTAGGCGCAGCATCCCTTTTCTACGGGTAGCGCGTATG
CC TGCGCGGCCTTCCGGAGCGAGGTGTGGGTGAGCGCAAAGGTGTCCCTAACCATGACTTTG
AG GTACTGGTATTTGAAGTCAGTGTCGTCGCATCCGCCCTGCTCCCAGAGCAAAAAGTCCGT
GC GCTTTTTGGAACGCGGGTTTGGCAGGGCGAAGGTGACATCGTTGAAGAGTATCTTTCCCG
CG CGAGGCATAAAGTTGCGTGTGATGCGGAAGGGTCCCGGCACCTCGGAACGGTTGTTAATT
AC CTGGGCGGCGAGCACGATCTCGTCAAAGCCGTTGATGTTGTGGCCCACAATGTAAAGTTC
CA AGAAGCGCGGGATGCCCTTGATGGAAGGCAATTTTTTAAGTTCCTCGTAGGTGAGCTCTT
CA GGGGAGCTGAGCCCGTGCTCTGAAAGGGCCCAGTCTGCAAGATGAGGGTTGGAAGCGACG
AA TGAGCTCCACAGGTCACGGGCCATTAGCATTTGCAGGTGGTCGCGAAAGGTCCTAAACTG
GC GACCTATGGCCATTTTTTCTGGGGTGATGCAGTAGAAGGTAAGCGGGTCTTGTTCCCAGC
GG TCCCATCCAAGGTCCGCGGCTAGGTCTCGCGCGGCGGTCACTAGAGGCTCATCTCCGCCG
AA CTTCATGACCAGCATGAAGGGCACGAGCTGCTTCCCAAAGGCCCCCATCCAAGTATAGGT
CT CTACATCGTAGGTGACAAAGAGACGCTCGGTGCGAGGATGCGAGCCGATCGGGAAGAACT
GG ATCTCCCGCCACCAGTTGGAGGAGTGGCTGTTGATGTGGTGAAAGTAGAAGTCCCTGCGA
CG GGCCGAACACTCGTGCTGGCTTTTGTAAAAACGTGCGCAGTACTGGCAGCGGTGCACGGG
CT GTACATCCTGCACGAGGTTGACCTGACGACCGCGCACAAGGAAGCAGAGTGGGAATTTGA
GC CCCTCGCCTGGCGGGTTTGGCTGGTGGTCTTCTACTTCGGCTGCTTGTCCTTGACCGTCT
GG CTGCTCGAGGGGAGTTACGGTGGATCGGACCACCACGCCGCGCGAGCCCAAAGTCCAGAT
GT CCGCGCGCGGCGGTCGGAGCTTGATGACAACATCGCGCAGATGGGAGCTGTCCATGGTCT
GG AGCTCCCGCGGCGTCAGGTCAGGCGGGAGCTCCTGCAGGTTTACCTCGCATAGCCGGGTC
AG GGCGCGGGCTAGGTCCAGGTGATACCTGATTTCCAGGGGCTGGTTGGTGGCGGCGTCGAT
GG CTTGCAAGAGGCCGCATCCCCGCGGCGCGACTACGGTACCGCGCGGCGGGCGGTGGGCCG
CG GGGGTGTCCTTGGATGATGCATCTAAAAGCGGTGACGCGGGCGGGCCCCCGGAGGTAGGG
GG GGCTCGGGACCCGCCGGGAGAGGGGGCAGGGGCACGTCGGCGCCGCGCGCGGGCAGGAGC
TG GTGCTGCGCGCGGAGGTTGCTGGCGAACGCGACGACGCGGCGGTTGATCTCCTGAATCTG
GC GCCTCTGCGTGAAGACGACGGGCCCGGTGAGCTTGAACCTGAAAGAGAGTTCGACAGAAT
CA ATTTCGGTGTCGTTGACGGCGGCCTGGCGCAAAATCTCCTGCACGTCTCCTGAGTTGTCT
TG ATAGGCGATCTCGGCCATGAACTGCTCGATCTCTTCCTCCTGGAGATCTCCGCGTCCGGC
TC GCTCCACGGTGGCGGCGAGGTCGTTGGAGATGCGGGCCATGAGCTGCGAGAAGGCGTTGA
GG CCTCCCTCGTTCCAGACGCGGCTGTAGACCACGCCCCCTTCGGCATCGCGGGCGCGCATG
AC CACCTGCGCGAGATTGAGCTCCACGTGCCGGGCGAAGACGGCGTAGTTTCGCAGGCGCTG
AA AGAGGTAGTTGAGGGTGGTGGCGGTGTGTTCTGCCACGAAGAAGTACATAACCCAGCGCC
GC AACGTGGATTCGTTGATATCCCCCAAGGCCTCAAGGCGCTCCATGGCCTCGTAGAAGTCC
AC GGCGAAGTTGAAAAACTGGGAGTTGCGCGCCGACACGGTTAACTCCTCCTCCAGAAGACG
GA TGAGCTCGGCGACAGTGTCGCGCACCTCGCGCTCAAAGGCTACAGGGGCCTCTTCTTCTT
CT TCAATCTCCTCTTCCATAAGGGCCTCCCCTTCTTCTTCTTCTGGCGGCGGTGGGGGAGGG
GG GACACGGCGGCGACGACGGCGCACCGGGAGGCGGTCGACAAAGCGCTCGATCATCTCCCC
GC GGCGACGGCGCATGGTCTCGGTGACGGCGCGGCCGTTCTCGCGGGGGCGCAGTTGGAAGA
CG CCGCCCGTCATGTCCCGGTTATGGGTTGGCGGGGGGCTGCCGTGCGGCAGGGATACGGCG
CT AACGATGCATCTCAACAATTGTTGTGTAGGTACTCCGCCACCGAGGGACCTGAGCGAGTC
CG CATCGACCGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTA
GG CTGAGCACCGTGGCGGGCGGCAGCGGGCGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTG
CT GATGATGTAATTAAAGTAGGCGGTCTTGAGACGGCGGATGGTCGACAGAAGCACCATGTC
CT TGGGTCCGGCCTGCTGAATGCGCAGGCGGTCGGCCATGCCCCAGGCTTCGTTTTGACATC
GG CGCAGGTCTTTGTAGTAGTCTTGCATGAGCCTTTCTACCGGCACTTCTTCTTCTCCTTCC
TC TTGTCCTGCATCTCTTGCATCTATCGCTGCGGCGGCGGCGGAGTTTGGCCGTAGGTGGCG
CC CTCTTCCTCCCATGCGTGTGACCCCGAAGCCCCTCATCGGCTGAAGCAGGGCCAGGTCGG
CG ACAACGCGCTCGGCTAATATGGCCTGCTGCACCTGCGTGAGGGTAGACTGGAAGTCGTCC
AT GTCCACAAAGCGGTGGTATGCGCCCGTGTTGATGGTGTAAGTGCAGTTGGCCATAACGGA
CC AGTTAACGGTCTGGTGACCCGGCTGCGAGAGCTCGGTGTACCTGAGACGCGAGTAAGCCC
TT GAGTCAAAGACGTAGTCGTTGCAAGTCCGCACCAGGTACTGGTATCCCACCAAAAAGTGC
GG CGGCGGCTGGCGGTAGAGGGGCCAGCGTAGGGTGGCCGGGGCTCCGGGGGCGAGGTCTTC
CA ACATAAGGCGATGATATCCGTAGATGTACCTGGACATCCAGGTGATGCCGGCGGCGGTGG
TG GAGGCGCGCGGAAAGTCACGGACGCGGTTCCAGATGTTGCGCAGCGGCAAAAAGTGCTCC
AT GGTCGGGACGCTCTGGCCGGTCAGGCGCGCGCAGTCGTTGACGCTCTAGACCGTGCAAAA
GG AGAGCCTGTAAGCGGGCACTCTTCCGTGGTCTGGTGGATAAATTCGCAAGGGTATCATGG
CG GACGACCGGGGTTCGAACCCCGGATCCGGCCGTCCGCCGTGATCCATGCGGTTACCGCCC
GC GTGTCGAACCCAGGTGTGCGACGTCAGACAACGGGGGAGCGCTCCTTTTGGCTTCCTTCC
AG GCGCGGCGGATGCTGCGCTAGCTTTTTTGGCCACTGGCCGCGCGCGGCGTAAGCGGTTAG
GC TGGAAAGCGAAAGCATTAAGTGGCTCGCTCCCTGTAGCCGGAGGGTTATTTTCCAAGGGT
TG AGTCGCGGGACCCCCGGTTCGAGTCTCGGGCCGGCCGGACTGCGGCGAACGGGGGTTTGC
CT CCCCGTCATGCAAGACCCCGCTTGCAAATTCCTCCGGAAACAGGGACGAGCCCCTTTTTT
GC TTTTCCCAGATGCATCCGGTGCTGCGGCAGATGCGCCCCCCTCCTCAGCAGCGGCAAGAG
CA AGAGCAGCGGCAGACATGCAGGGCACCCTCCCCTCCTCCTACCGCGTCAGGAGGGGCGAC
AT CCGCGGTTGACGCGGCAGCAGATGGTGATTACGAACCCCCGCGGCGCCGGGCCCGGCACT
AC CTGGACTTGGAGGAGGGCGAGGGCCTGGCGCGGCTAGGAGCGCCCTCTCCTGAGCGGTAC
CC AAGGGTGCAGCTGAAGCGTGATACGCGTGAGGCGTACGTGCCGCGGCAGAACCTGTTTCG
CG ACCGCGAGGGAGAGGAGCCCGAGGAGATGCGGGATCGAAAGTTCCACGCAGGGCGCGAGC
TG CGGCATGGCCTGAATCGCGAGCGGTTGCTGCGCGAGGAGGACTTTGAGCCCGACGCGCGA
AC CGGGATTAGTCCCGCGCGCGCACACGTGGCGGCCGCCGACCTGGTAACCGCATACGAGCA
GA CGGTGAACCAGGAGATTAACTTTCAAAAAAGCTTTAACAACCACGTGCGTACGCTTGTGG
CG CGCGAGGAGGTGGCTATAGGACTGATGCATCTGTGGGACTTTGTAAGCGCGCTGGAGCAA
AA CCCAAATAGCAAGCCGCTCATGGCGCAGCTGTTCCTTATAGTGCAGCACAGCAGGGACAA
CG AGGCATTCAGGGATGCGCTGCTAAACATAGTAGAGCCCGAGGGCCGCTGGCTGCTCGATT
TG ATAAACATCCTGCAGAGCATAGTGGTGCAGGAGCGCAGCTTGAGCCTGGCTGACAAGGTG
GC CGCCATCAACTATTCCATGCTTAGCCTGGGCAAGTTTTACGCCCGCAAGATATACCATAC
CC CTTACGTTCCCATAGACAAGGAGGTAAAGATCGAGGGGTTCTACATGCGCATGGCGCTGA
AG GTGCTTACCTTGAGCGACGACCTGGGCGTTTATCGCAACGAGCGCATCCACAAGGCCGTG
AG CGTGAGCCGGCGGCGCGAGCTCAGCGACCGCGAGCTGATGCACAGCCTGCAAAGGGCCCT
GG CTGGCACGGGCAGCGGCGATAGAGAGGCCGAGTCCTACTTTGACGCGGGCGCTGACCTGC
GC TGGGCCCCAAGCCGACGCGCCCTGGAGGCAGCTGGGGCCGGACCTGGGCTGGCGGTGGCA
CC CGCGCGCGCTGGCAACGTCGGCGGCGTGGAGGAATATGACGAGGACGATGAGTACGAGCC
AG AGGACGGCGAGTACTAAGCGGTGATGTTTCTGATCAGTCGCGGCCGCGATATCGCTAGCG
AA GTTCCTATTCTCTAGAAAGTATAGGAACTTCGGATCCTCTAGAGTCGAAAAAAAAAAAGC
AT GATGCAAAATAAAAAACTCACCAAGGCCATGGCACCGAGCGTTGGTTTTCTTGTATTCCC
CT TAGTATGCGGCGCGCGGCGATGTATGAGGAAGGTCCTCCTCCCTCCTACGAGAGTGTGGT
GA GCGCGGCGCCAGTGGCGGCGGCGCTGGGTTCTCCCTTCGATGCTCCCCTGGACCCGCCGT
TT GTGCCTCCGCGGTACCTGCGGCCTACCGGGGGGAGAAACAGCATCCGTTACTCTGAGTTG
GC ACCCCTATTCGACACCACCCGTGTGTACCTGGTGGACAACAAGTCAACGGATGTGGCATC
CC TGAACTACCAGAACGACCACAGCAACTTTCTGACCACGGTCATTCAAAACAATGACTACA
GC CCGGGGGAGGCAAGCACACAGACCATCAATCTTGACGACCGGTCGCACTGGGGCGGCGAC
CT GAAAACCATCCTGCATACCAACATGCCAAATGTGAACGAGTTCATGTTTACCAATAAGTT
TA AGGCGCGGGTGATGGTGTCGCGCTTGCCTACTAAGGACAATCAGGTGGAGCTGAAATACG
AG TGGGTGGAGTTCACGCTGCCCGAGGGCAACTACTCCGAGACCATGACCATAGACCTTATG
AA CAACGCGATCGTGGAGCACTACTTGAAAGTGGGCAGACAGAACGGGGTTCTGGAAAGCGA
CA TCGGGGTAAAGTTTGACACCCGCAACTTCAGACTGGGGTTTGACCCCGTCACTGGTCTTG
TC ATGCCTGGGGTATATACAAACGAAGCCTTCCATCCAGACATCATTTTGCTGCCAGGATGC
GG GGTGGACTTCACCCACAGCCGCCTGAGCAACTTGTTGGGCATCCGCAAGCGGCAACCCTT
CC AGGAGGGCTTTAGGATCACCTACGATGATCTGGAGGGTGGTAACATTCCCGCACTGTTGG
AT GTGGACGCCTACCAGGCGAGCTTGAAAGATGACACCGAACAGGGCGGGGGTGGCGCAGGC
GG CAGCAACAGCAGTGGCAGCGGCGCGGAAGAGAACTCCAACGCGGCAGCCGCGGCAATGCA
GC CGGTGGAGGACATGAACGATCATGCCATTCGCGGCGACACCTTTGCCACACGGGCTGAGG
AG AAGCGCGCTGAGGCCGAAGCAGCGGCCGAAGCTGCCGCCCCCGCTGCGCAACCCGAGGTC
GA GAAGCCTCAGAAGAAACCGGTGATCAAACCCCTGACAGAGGACAGCAAGAAACGCAGTTA
CA ACCTAATAAGCAATGACAGCACCTTCACCCAGTACCGCAGCTGGTACCTTGCATACAACT
AC GGCGACCCTCAGACCGGAATCCGCTCATGGACCCTGCTTTGCACTCCTGACGTAACCTGC
GG CTCGGAGCAGGTCTACTGGTCGTTGCCAGACATGATGCAAGACCCCGTGACCTTCCGCTC
CA CGCGCCAGATCAGCAACTTTCCGGTGGTGGGCGCCGAGCTGTTGCCCGTGCACTCCAAGA
GC TTCTACAACGACCAGGCCGTCTACTCCCAACTCATCCGCCAGTTTACCTCTCTGACCCAC
GT GTTCAATCGCTTTCCCGAGAACCAGATTTTGGCGCGCCCGCCAGCCCCCACCATCACCAC
CG TCAGTGAAAACGTTCCTGCTCTCACAGATCACGGGACGCTACCGCTGCGCAACAGCATCG
GA GGAGTCCAGCGAGTGACCATTACTGACGCCAGACGCCGCACCTGCCCCTACGTTTACAAG
GC CCTGGGCATAGTCTCGCCGCGCGTCCTATCGAGCCGCACTTTTTGAGCAAGCATGTCCAT
CC TTATATCGCCCAGCAATAACACAGGCTGGGGCCTGCGCTTCCCAAGCAAGATGTTTGGCG
GG GCCAAGAAGCGCTCCGACCAACACCCAGTGCGCGTGCGCGGGCACTACCGCGCGCCCTGG
GG CGCGCACAAACGCGGCCGCACTGGGCGCACCACCGTCGATGACGCCATCGACGCGGTGGT
GG AGGAGGCGCGCAACTACACGCCCACGCCGCCGCCAGTGTCCACCGTGGACGCGGCCATTC
AG ACCGTGGTGCGCGGAGCCCGGCGCTACGCTAAAATGAAGAGACGGCGGAGGCGCGTAGCA
CG TCGCCACCGCCGCCGACCCGGCACTGCCGCCCAACGCGCGGCGGCGGCCCTGCTTAACCG
CG CACGTCGCACCGGCCGACGGGCGGCCATGCGAGCCGCTCGAAGGCTGGCCGCGGGTATTG
TC ACTGTGCCCCCCAGGTCCAGGCGACGAGCGGCCGCCGCAGCAGCCGCGGCCATTAGTGTT
AT GACTCAGGGTCGCAGGGGCAACGTGTACTGGGTGCGCGACTCGGTTAGCGGCCTGCGCGT
GC CCGTGCGCACCCGCCCCCCGCGCAACTAGATTGCAATAAAAAACTACTTAGACTCGTACT
GT TGTATGTATCCAGCGGCGGCGGCGCGCATCGAAGCTATGTCCAAGCGCAAAATCAAAGAA
GA GATGCTCCAGGTCATCGCGCCGGAGATCTATGGCCCCCCGAAGAAGGAAGAGCAGGATTA
CA AGCCCCGAAAGCTAAAGCGGGTCAAAAAGAAAAAGAAAGATGATGATGATGATGAACTTG
AC GACGAGGTGGAACTGTTGCACGCGACCGCGCCCAGGCGACGGGTACAGTGGAAAGGTCGA
CG CGTAAGACGTGTTTTGCGACCCGGCACCACCGTAGTCTTTACGCCCGGTGAGCGCTCCAC
CC GCACCTACAAGCGCGTGTATGATGAGGTGTACGGCGACGAGGACCTGCTTGAGCAGGCCA
AC GAGCGCCTCGGGGAGTTTGCCTACGGAAAGCGGCATAAGGACATGCTGGCGTTGCCGCTG
GA CGAGGGCAACCCAACACCTAGCCTAAAGCCCGTGACACTGCAGCAGGTGCTGCCCGCGCT
TG CACCGTCCGAAGAAAAGCGCGGCCTAAAGCGCGAGTCTGGTGACTTGGCACCCACCGTGC
AG CTGATGGTACCCAAGCGTCAGCGACTGGAAGATGTCTTGGAAAAAATGACCGTGGAGCCT
GG GCTGGAGCCCGAGGTCCGCGTGCGGCCAATCAAGCAGGTGGCACCGGGACTGGGCGTGCA
GA CCGTGGACGTTCAGATACCCACCACCAGTAGCACTAGTATTGCCACTGCCACAGAGGGCA
TG GAGACACAAACGTCCCCGGTTGCCTCGGCGGTGGCAGATGCCGCGGTGCAGGCGGCCGCT
GC GGCCGCGTCCAAGACCTCTACGGAGGTGCAAACGGACCCGTGGATGTTTCGTGTTTCAGC
CC CCCGGCGTCCGCGCCGTTCAAGGAAGTACGGCGCCGCCAGCGCGCTACTGCCCGAATATG
CC CTACATCCTTCCATCGCGCCTACCCCCGGCTATCGTGGCTACACCTACCGCCCCAGAAGA
CG AGCAACTACCCGACGCCGAACCACCACTGGAACCCGCCGCCGCCGTCGCCGTCGCCAGCC
CG TGCTGGCCCCGATTTCCGTGCGCAGGGTGGCTCGCGAAGGAGGCAGGACCCTGGTGCTGC
CA ACAGCGCGCTACCACCCCAGCATCGTTTAAAAGCCGGTCTTTGTGGTTCTTGCAGATATG
GC CCTCACCTGCCGCCTCCGTTTCCCGGTGCCGGGATTCCGAGGAAGAATGCACCGTAGGAG
GG GCATGGCCGGCCACGGCCTGACGGGCGGCATGCGTCGTGCGCACCACCGGCGGCGGCGCG
CG TCGCACCGTCGCATGCGCGCCGGTATCCTGCCCCTCCTTATTCCACTGATCGCCGCGGCG
AT TGGCGCCGTGCCCGGAATTGCATCCGTGGCCTTGCAGGCGCAGAGACACTGATTAAAAAC
AA GTTACATGTGGAAAAATCAAAATAAAAGTCTGGACTCTCACGCTCGCTTGGTCCTGTAAC
TA TTTTGTAGAATGGAAGACATCAACTTTGCGTCACTGGCCCCGCGACACGGCTCGCGCCCG
TT CATGGGAAACTGGCAAGATATCGGCACCAGCAATATGAGCGGTGGCGCCTTCAGCTGGGG
CT CGCTGTGGAGCGGCATTAAAAATTTCGGTTCCGCCGTTAAGAACTATGGCAGCAAAGCCT
GG AACAGCAGCACAGGCCAGATGCTGAGGGACAAGTTGAAAGAGCAAAATTTCCAACAAAAG
GT GGTAGATGGCCTGGCCTCTGGCATTAGCGGGGTGGTGGACCTGGCCAACCAGGCAGTGCA
AA ATAAGATTAACAGTAAGCTTGATCCCCGCCCTCCCGTAGAGGAGCCTCCACCGGCCGTGG
AG ACAGTGTCTCCAGAGGGGCGTGGCGAAAAGCGTCCGCGACCCGACAGGGAAGAAACTCTG
GT GACGCAAATAGACGAGCCTCCCTCGTACGAGGAGGCACTAAAGCAAGGCCTGCCCACCAC
CC GTCCCATCGCGCCCATGGCTACCGGAGTGCTGGGCCAGCACACACCCGTAACGCTGGACC
TG CCTCCCCCCGCCGACACCCAGCAGAAACCTGTGCTGCCAGGCCCGTCCGCCGTTGTTGTA
AC CCGTCCTAGCCGCGGGTCCCTGCGCCGCGCCGCCAGCGGTCCGCGATCGTTGCGGCCCGT
AG CCAGTGGCAACTGGCAAAGCACACTGAACAGCATCGTGGGTTTGGGGGTGCAATCCCTGA
AG CGCCGACGATGCTTCTGATAGCTAACGTGTCGTATGTGTGTCATGTATGCGTCCATGTCG
CC GCCAGAGGAGCTGCTGAGCCGCCGCGCGCCCGCTTTCCAAGATGGCTACCCCTTCGATGA
TG CCGCAGTGGTCTTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCCCGGG
CT GGTGCAGTTCGCCCGCGCCACCGAGACGTACTTCAGCCTGAATAACAAGTTTAGAAACCC
CA CGGTGGCGCCTACGCACGACGTGACCACAGACCGGTCTCAGCGTTTGACGCTGCGGTTCA
TC CCCGTGGACCGCGAGGATACTGCGTACTCGTACAAGGCGCGGTTCACCCTAGCTGTGGGT
GA TAACCGTGTGCTAGACATGGCTTCCACGTACTTTGACATCCGCGGCGTGCTGGACAGGGG
CC CTACTTTTAAGCCCTACTCTGGCACTGCCTACAACGCACTGGCCCCCAAGGGTGCCCCCA
AC TCGTGCGAGTGGGAACAAAATGAAACTGCACAAGTGGATGCTCAAGAACTTGACGAAGAG
GA GAATGAAGCCAATGAAGCTCAGGCGCGAGAACAGGAACAAGCTAAGAAAACCCATGTATA
TG CCCAGGCTCCACTGTCCGGAATAAAAATAACTAAAGAAGGTCTACAAATAGGAACTGCCG
AC GCCACAGTAGCAGGTGCCGGCAAAGAAATTTTCGCAGACAAAACTTTTCAACCTGAACCA
CA AGTAGGAGAATCTCAATGGAACGAAGCGGATGCCACAGCAGCTGGTGGAAGGGTTCTTAA
AA AGACAACTCCCATGAAACCCTGCTATGGCTCATACGCTAGACCCACCAATTCCAACGGCG
GA CAGGGCGTTATGGTTGAACAAAATGGTAAATTGGAAAGTCAAGTCGAAATGCAATTTTTT
TC CACATCCACAAATGCCACAAATGAAGTTAACAATATACAACCAACAGTTGTATTGTACAG
CG AAGATGTAAACATGGAAACTCCAGATACTCATCTTTCTTATAAACCTAAAATGGGGGATA
AA AATGCCAAAGTCATGCTTGGACAACAAGCAATGCCAAACAGACCAAATTACATTGCTTTT
AG AGACAATTTTATTGGTCTCATGTATTACAACAGCACAGGTAACATGGGTGTCCTTGCTGG
TC AGGCATCGCAGTTGAACGCTGTTGTAGATTTGCAAGACAGAAACACAGAGCTGTCCTACC
AG CTTTTGCTTGATTCAATTGGCGACAGAACAAGATACTTTTCAATGTGGAATCAAGCTGTT
GA CAGCTATGATCCAGATGTCAGAATTATTGAGAACCATGGAACTGAGGATGAGTTGCCAAA
TT ATTGCTTTCCTCTTGGTGGAATTGGGATTACTGACACTTTTCAAGCTGTTAAAACAACTG
CT GCTAACGGGGACCAAGGCAATACTACCTGGCAAAAAGATTCAACATTTGCAGAACGCAAT
GA AATAGGGGTGGGAAATAACTTTGCCATGGAAATTAACCTGAATGCCAACCTATGGAGAAA
TT TCCTTTACTCCAATATTGCGCTGTACCTGCCAGACAAGCTAAAATACAACCCCACCAATG
TG GAAATATCTGACAACCCCAACACCTACGACTACATGAACAAGCGAGTGGTGGCTCCTGGG
CT TGTAGACTGCTACATTAACCTTGGGGCGCGCTGGTCTCTGGACTACATGGACAACGTTAA
TC CCTTTAACCACCCCCGCCATGCGGGCCTGCGTTACCGCTCCATGTTGTTGGGAAACGGCC
GC TACGTGCCCTTTCACATTCAGGTGCCCCAAAAGTTTTTTGCCATTAAAAACCTCCTCCTC
CT GCCAGGCTCATACACATATGAATGGAACTTCAGGAAGGATGTTAACATGGTTCTGCAGAG
CT CTCTGGGAAACGACCTTAGAGTTGACGGGGCTAGCATTAAGTTTGACAGCATTTGTCTTT
AC GCCACCTTCTTCCCCATGGCCCACAACACGGCCTCCACGCTGGAAGCCATGCTCAGAAAT
GA CACCAACGACCAGTCCTTTAATGACTACCTTTCCGCCGCCAACATGCTATATCCCATACC
CG CCAACGCCACCAACGTGCCCATCTCCATCCCATCGCGCAACTGGGCAGCATTTCGCGGTT
GG GCCTTCACACGCTTGAAGACAAAGGAAACCCCTTCCCTGGGATCAGGCTACGACCCTTAC
TA CACCTACTCTGGCTCCATACCATACCTTGACGGAACCTTCTATCTTAATCACACCTTTAA
GA AGGTGGCCATTACTTTTGACTCTTCTGTTAGCTGGCCGGGCAACGACCGCCTGCTTACTC
CC AATGAGTTTGAGATTAAGCGCTCAGTTGACGGGGAGGGCTATAACGTAGCTCAGTGCAAC
AT GACAAAGGACTGGTTCCTAGTGCAGATGTTGGCCAACTACAATATTGGCTACCAGGGCTT
CT ACATTCCAGAAAGCTACAAAGACCGCATGTACTCGTTCTTCAGAAACTTCCAGCCCATGA
GC CGGCAAGTGGTGGACGATACTAAATACAAAGATTATCAGCAGGTTGGAATTATCCACCAG
CA TAACAACTCAGGCTTCGTAGGCTACCTCGCTCCCACCATGCGCGAGGGACAAGCTTACCC
CG CTAATGTTCCCTACCCACTAATAGGCAAAACCGCGGTTGATAGTATTACCCAGAAAAAGT
TT CTTTGCGACCGCACCCTGTGGCGCATCCCCTTCTCCAGTAACTTTATGTCCATGGGTGCG
CT CACAGACCTGGGCCAAAACCTTCTCTACGCAAACTCCGCCCACGCGCTAGACATGACCTT
TG AGGTGGATCCCATGGACGAGCCCACCCTTCTTTATGTTTTGTTTGAAGTCTTTGACGTGG
TC CGTGTGCACCAGCCGCACCGCGGCGTCATCGAGACCGTGTACCTGCGCACGCCCTTCTCG
GC CGGCAACGCCACAACATAAAGAAGCAAGCAACATCAACAACAGCTGCCGCCATGGGCTCC
AG TGAGCAGGAACTGAAAGCCATTGTCAAAGATCTTGGTTGTGGGCCATATTTTTTGGGCAC
CT ATGACAAGCGCTTCCCAGGCTTTGTTTCCCCACACAAGCTCGCCTGCGCCATAGTTAACA
CG GCCGGTCGCGAGACTGGGGGCGTACACTGGATGGCCTTTGCCTGGAACCCGCGCTCAAAA
AC ATGCTACCTCTTTGAGCCCTTTGGCTTTTCTGACCAACGTCTCAAGCAGGTTTACCAGTT
TG AGTACGAGTCACTCCTGCGCCGTAGCGCCATTGCCTCTTCCCCCGACCGCTGTATAACGC
TG GAAAAGTCCACCCAAAGCGTGCAGGGGCCCAACTCGGCCGCCTGTGGCCTATTCTGCTGC
AT GTTTCTCCACGCCTTTGCCAACTGGCCCCAAACTCCCATGGATCACAACCCCACCATGAA
CC TTATTACCGGGGTACCCAACTCCATGCTTAACAGTCCCCAGGTACAGCCCACCCTGCGCC
GC AACCAGGAACAGCTCTACAGCTTCCTGGAGCGCCACTCGCCCTACTTCCGCAGCCACAGT
GC GCAAATTAGGAGCGCCACTTCTTTTTGTCACTTGAAAAACATGTAAAAATAATGTACTAG
GA GACACTTTCAATAAAGGCAAATGTTTTTATTTGTACACTCTCGGGTGATTATTTACCCCC
AC CCTTGCCGTCTGCGCCGTTTAAAAATCAAAGGGGTTCTGCCGCGCATCGCTATGCGCCAC
TG GCAGGGACACGTTGCGATACTGGTGTTTAGTGCTCCACTTAAACTCAGGCACAACCATCC
GC GGCAGCTCGGTGAAGTTTTCACTCCACAGGCTGCGCACCATCACCAACGCGTTTAGCAGG
TC GGGCGCCGATATCTTGAAGTCGCAGTTGGGGCCTCCGCCCTGCGCGCGCGAGTTGCGATA
CA CAGGGTTACAGCACTGGAACACTATCAGCGCCGGGTGGTGCACGCTGGCCAGCACGCTCT
TG TCGGAGATCANATCCGCGTCCAGGTCCTCCGCGTTGCTCAGGGCGAACGGAGTCAACTTT
GG TAGCTGCCTTCCCAAAAAGGGTGCATGCCCAGGCTTTGAGTTGCACTCGCACCGTAGTGG
CA TCAGAAGGTGACCGTGCCCAGTCTGGGCGTTAGGATACAGCGCCTGCATGAAAGCCTTGA
TC TGCTTAAAAGCCACCTGAGCCTTTGCGCCTTCAGAGAAGAACATGCCGCAAGACTTGCCG
GA AAACTGATTGGCCGGACAGGCCGCGTCATGCACGCAGCACCTTGCGTCGGTGTTGGAGAT
CT GCACCACATTTCGGCCCCACCGGTTCTTCACGATCTTGGCCTTGCTAGACTGCTCCTTCA
GC GCGCGCTGCCCGTTTTCGCTCGTCACATCCATTTCAATCACGTGCTCCTTATTTATCATA
AT GCTCCCGTGTAGACACTTAAGCTCGCCTTCGATCTCAGCGCAGCGGTGCAGCCACAACGC
GC AGCCCGTGGGCTCGTGGTGCTTGTAGGTTACCTCTGCAAACGACTGCAGGTACGCCTGCA
GG AATCGCCCCATCATCGTCACAAAGGTCTTGTTGCTGGTGAAGGTCAGCTGCAACCCGCGG
TG CTCCTCGTTTAGCCAGGTCTTGCATACGGCCGCCAGAGCTTCCACTTGGTCAGGCAGTAG
CT TGAAGTTTGCCTTTAGATCGTTATCCACGTGGTACTTGTCCATCAACGCGCGCGCAGCCT
CC ATGCCCTTCTCCCACGCAGACACGATCGGCAGGCTCAGCGGGTTTATCACCGTGCTTTCA
CT TTCCGCTTCACTGGACTCTTCCTTTTCCTCTTGCATCCGCATACCCCGCGCCACTGGGTC
GT CTTCATTCAGCCGCCGCACCGTGCGCTTACCTCCCTTGCCGTGCTTGATTAGCACCGGTG
GG TTGCTGAAACCCACCATTTGTAGCGCCACATCTTCTCTTTCTTCCTCGCTGTCCACGATC
AC CTCTGGGGATGGCGGGCGCTCGGGCTTGGGAGAGGGGCGCTTCTTTTTCTTTTTGGACGC
AA TGGCCAAATCCGCCGTCGAGGTCGATGGCCGCGGGCTGGGTGTGCGCGGCACCAGCGCAT
CT TGTGACGAGTCTTCTTCGTCCTCGGACTCGAGACGCCGCCTCAGCCGCTTTTTTGGGGGC
GC GCGGGGAGGCGGCGGCGACGGCGACGGGGACGAGACGTCCTCCATGGTTGGTGGACGTCG
CG CCGCACCGCGTCCGCGCTCGGGGGTGGTTTCGCGCTGCTCCTCTTCCCGACTGGCCATTT
CC TTCTCCTATAGGCAGAAAAAGATCATGGAGTCAGTCGAGAAGGAGGACAGCCTAACCGCC
CC CTTTGAGTTCGCCACCACCGCCTCCACCGATGCCGCCAACGCGCCTACCACCTTCCCCGT
CG AGGCACCCCCGCTTGAGGAGGAGGAAGTGATTATCGAGCAGGACCCAGGTTTTGTAAGCG
AA GACGACGAAGATCGCTCAGTACCAACAGAGGATAAAAAGCAAGACCAGGACGACGCAGAG
GC AAACGAGGAACAAGTCGGGCGGGGGGACCAAAGGCATGGCGACTACCTAGATGTGGGAGA
CG ACGTGCTGTTGAAGCATCTGCAGCGCCAGTGCGCCATTATCTGCGACGCGTTGCAAGAGC
GC AGCGATGTGCCCCTCGCCATAGCGGATGTCAGCCTTGCCTACGAACGCCACCTGTTCTCA
CC GCGCGTACCCCCCAAACGCCAAGAAAACGGCACATGCGAGCCCAACCCGCGCCTCAACTT
CT ACCCCGTATTTGCCGTGCCAGAGGTGCTTGCCACCTATCACATCTTTTTCCAAAACTGCA
AG ATACCCCTATCCTGCCGTGCCAACCGCAGCCGAGCGGACAAGCAGCTGGCCTTGCGGCAG
GG CGCTGTCATACCTGATATCGCCTCGCTCGACGAAGTGCCAAAAATCTTTGAGGGTCTTGG
AC GCGACGAGAAGCGCGCGGCAAACGCTCTGCAACAAGAAAACAGCGAAAATGAAAGTCACT
GT GGAGTGCTGGTGGAACTTGAGGGTGACAACGCGCGCCTAGCCGTGCTGAAACGCAGCATC
GA GGTCACCCACTTTGCCTACCCGGCACTTAACCTACCCCCCAAGGTTATGAGCACAGTCAT
GA GCGAGCTGATCGTGCGCCGTGCACGACCCCTGGAGAGGGATGCAAACTTGCAAGAACAAA
CC GAGGAGGGCCTACCCGCAGTTGGCGATGAGCAGCTGGCGCGCTGGCTTGAGACGCGCGAG
CC TGCCGACTTGGAGGAGCGACGCAAGCTAATGATGGCCGCAGTGCTTGTTACCGTGGAGCT
TG AGTGCATGCAGCGGTTCTTTGCTGACCCGGAGATGCAGCGCAAGCTAGAGGAAACGTTGC
AC TACACCTTTCGCCAGGGCTACGTGCGCCAGGCCTGCAAAATTTCCAACGTGGAGCTCTGC
AA CCTGGTCTCCTACCTTGGAATTTTGCACGAAAACCGCCTTGGGCAAAACGTGCTTCATTC
CA CGCTCAAGGGCGAGGCGCGCCGCGACTACGTCCGCGACTGCGTTTACTTATTTCTGTGCT
AC ACCTGGCAAACGGCCATGGGCGTGTGGCAGCAGTGCCTGGAGGAGCGCAACCTGAAGGAG
CT GCAGAAGCTGCTAAAGCAAAACTTGAAGGACCTATGGACGGCCTTCAACGAGCGCTCCGT
GG CCGCGCACCTGGCGGACATTATCTTCCCCGAACGCCTGCTTAAAACCCTGCAACAGGGTC
TG CCAGACTTCACCAGTCAAAGCATGTTGCAAAACTTTAGGAACTTTATCCTAGAGCGTTCA
GG AATTCTGCCCGCCACCTGCTGTGCGCTTCCTAGCGACTTTGTGCCCATTAAGTACCGTGA
AT GCCCTCCGCCGCTTTGGGGTCACTGCTACCTTNTGCAGCTAGCCAACTACCTTGCCTACC
AC TCCGACATCATGGAAGACGTGAGCGGTGACGGCCTACTGGAGTGTCACTGTCGCTGCAAC
CT ATGCACCCCGCACCGCTCCCTGGTCTGCAATTCACAACTGCTTAGCGAAAGTCAAATTAT
CG GTACCTTTGAGCTGCAGGGTCCCTCGCCTGACGAAAAGTCCGCGGCTCCGGGGTTGAAAC
TC ACTCCGGGGCTGTGGACGTCGGCTTACCTTCGCAAATTTGTACCTGAGGACTACCACGCC
CA CGAGATTAGGTTCTACGAAGACCAATCCCGCCCGCCAAATGCGGAGCTTACCGCCTGCGT
CA TTACCCAGGGCCACATCCTTGGCCAATTGCAAGCCATTAACAAAGCCCGCCAAGAGTTTC
TG CTACGAAAGGGACGGGGGGTTTACTTGGACCCCCAGTCCGGCGAGGAGCTCAACCCAATC
CC CCCGCCGCCGCAGCCCTATCAGCAGCCGCGGGCCCTTGCTTCCCAGGATGGCACCCAAAA
AG AAGCTGCAGCTGCCGCCGCCGCCACCCACGGACGAGGAGGAATACTGGGACAGTCAGGCA
GA GGAGGTTTTGGACGAGGAGGAGGAGATGATGGAAGACTGGGACAGCCTAGACGAGGAAGC
TT CCGAGGCCGAAGAGGTGTCAGACGAAACACCGTCACCCTCGGTCGCATTCCCCTCGCCGG
CG CCCCAGAAATCGGCAACCGTTCCCAGCATTGCTACAACCTCCGCTCCTCAGGCGCCGCCG
GC ACTGCCCGTTCGCCGACCCAACCGTAGATGGGACACCACTGGAACCAGGGCCGGTAAGTC
TA AGCAGCCGCCGCCGTTAGCCCAAGAGCAACAACAGCGCCAAGGCTACCGCTCGTGGCGCG
TG CACAAGAACGCCATAGTTGCTTGCTTGCAAGACTGTGGGGGCAACATCTCCTTCGCCCGC
CG CTTTCTTCTCTACCATCACGGCGTGGCCTTCCCCCGTAACATCCTGCATTACTACCGTCA
TC TCTACAGCCCCTACTGCACCGGCGGCAGCGGCAGCAACAGCAGCGGCCACGCAGAAGCAA
AG GCGACCGGATAGCAAGACTCTGACAAAGCCCAAGAAATCCACAGCGGCGGCAGCAGCAGG
AG GAGGAGCACTGCGTCTGGCGCCCAACGAACCCGTATCGACCCGCGAGCTTAGAAACAGGA
TT TTTCCCACTCTGTATGCTATATTTCAACAGAGCAGGGGCCAAGAACAAGAGCTGAAAATA
AA AAACAGGTCTCTGCGCTCCCTCACCCGCAGCTGCCTGTATCACAAAAGCGAAGATCAGCT
TC GGCGCACGCTGGAAGACGCGGAGGCTCTCTTCAGCAAATACTGCGCGCTGACTCTTAAGG
AC TAGTTTCGCGCCCTTTCTCAAATTTAAGCGCGAAAACTACGTCATCTCCAGCGGCCACAC
CC GGCGCCAGCACCTGTCGTCAGCGCCATTATGAGCAAGGAAATTCCCACGCCCTACATGTG
GA GTTACCAGCCACAAATGGGACTTGCGGCTGGAGCTGCCCAAGACTACTCAACCCGAATAA
AC TACATGAGCGCGGGACCCCACATGATATCCCGGGTCAACGGAATCCGCGCCCACCGAAAC
CG AATTCTCCTCGAACAGGCGGCTATTACCACCACACCTCGTAATAACCTTAATCCCCGTAG
TT GGCCCGCTGCCCTGGTGTACCAGGAAAGTCCCGCTCCCACCACTGTGGTACTTCCCAGAG
AC GCCCAGGCCGAAGTTCAGATGACTAACTCAGGGGCGCAGCTTGCGGGCGGCTTTCGTCAC
AG GGTGCGGTCGCCCGGGCAGGGTATAACTCACCTGAAAATCAGAGGGCGAGGTATTCAGCT
CA ACGACGAGTCGGTGAGCTCCTCTCTTGGTCTCCGTCCGGACGGGACATTTCAGATCGGCG
GC GCTGGCCGCTCTTCATTTACGCCCCGTCAGGCGATCCTAACTCTGCAGACCTCGTCCTCG
GA GCCGCGCTCCGGAGGCATTGGAACTCTACAATTTATTGAGGAGTTCGTGCCTTCGGTTTA
CT TCAACCCCTTTTCTGGACCTCCCGGCCACTACCCGGACCAGTTTATTCCCAACTTTGACG
CG GTAAAAGACTCGGCGGACGGCTACGACTGACAGATCTGAGCTCGCGGCCGCGATATCGCT
AG CGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCGATCCTCTAGAGTCGACCTGCAGGC
AT GCAAGCTTGGCACTGCAATAAATTACTTACTTAAAATCAGTCAGCAAATCTTTGTCCAGC
TT ATTCAGCATCACCTCCTTTCCCTCCTCCCAACTCTGGTATTTCAGCAGCCTTTTAGCTGC
GA ACTTTCTCCAAAGTCTAAATGGGATGTCAAATTCCTCATGTTCTTGTCCCTCCGCACCCA
CT ATCTTCATATTGTTGCAGATGAAACGCGCCAGACCGTCTGAAGACACCTTCAACCCTGTG
TA CCCATATGACACGGAAACCGGCCCTCCAACTGTGCCTTTCCTTACCCCTCCCTTTGTGTC
GC CAAATGGGTTCCAAGAAAGTCCCCCCGGAGTGCTTTCTTTGCGTCTTTCAGAACCTTTGG
TT ACCTCACACGGCATGCTTGCGCTAAAAATGGGCAGCGGCCTGTCCCTGGATCAGGCAGGC
AA CCTTACATCAAATACAATCACTGTTTCTCAACCGCTAAAAAAAACAAAGTCCAATATAAC
TT TGGAAACATCCGCGCCCCTTACAGTCAGCTCAGGCGCCCTAACCATGGCCACAACTTCGC
CT TTGGTGGTCTCTGACAACACTCTTACCATGCAATCACAAGCACCGCTAACCGTGCAAGAC
TC AAAACTTAGCATTGCTACCAAAGAGCCACTTACAGTGTTAGATGGAAAACTGGCCCTGCA
GA CATCAGCCCCCCTCTCTGCCACTGATAACAACGCCCTCACTATCACTGCCTCACCTCCTC
TT ACTACTGCAAATGGTAGTCTGGCTGTTACCATGGAAAACCCACTTTACAACAACAATGGA
AA ACTTGGGCTCAAAATTGGCGGTCCTTTGCAAGTGGCCACCGACTCACATGCACTAACACT
AG GTACTGGTCAGGGGGTTGCAGTTCATAACAATTTGCTACATACAAAAGTTACAGGCGCAA
TA GGGTTTGATACATCTGGCAACATGGAACTTAAAACTGGAGATGGCCTCTATGTGGATAGC
GC CGGTCCTAACCAAAAACTACATATTAATCTAAATACCACAAAAGGCCTTGCTTTTGACAA
CA CCGCAATAACAATTAACGCTGGAAAAGGGTTGGAATTTGAAACAGACTCCTCAAACGGAA
AT CCCATAAAAACAAAAATTGGATCAGGCATACAATATAATACCAATGGAGCTATGGTTGCA
AA ACTTGGAACAGGCCTCAGTTTTGACAGCTCCGGAGCCATAACAATGGGCAGCATAAACAA
TG ACAGACTTACTCTTTGGACAACACCAGACCCATCCCCAAATTGCAGAATTGCTTCAGATA
AA GACTGCAAGCTAACTCTGGCGCTAACAAAATGTGGCAGTCAAATTTTGGGCACTGTTTCA
GC TTTGGCAGTATCAGGTAATATGGCCTCCATCAATGGAACTCTAAGCAGTGTAAACTTGGT
TC TTAGATTTGATGACAACGGAGTGCTTATGTCAAATTCATCACTGGACAAACAGTATTGGA
AC TTTAGAAACGGGGACTCCACTAACGGTCAACCATACACTTATGCTGTTGGGTTTATGCCA
AA CCTAAAAGCTTACCCAAAAACTCAAAGTAAAACTGCAAAAAGTAATATTGTTAGCCAGGT
GT ATCTTAATGGTGACAAGTCTAAACCATTGCATTTTACTATTACGCTAAATGGAACAGATG
AA ACCAACCAAGTAAGCAAATACTCAATATCATTCAGTTGGTCCTGGAACAGTGGACAATAC
AC TAATGACAAATTTGCCACCAATTCCTATACCTTCTCCTACATTGCCCAGGAATAAAGAAT
CG TGAACCTGTTGCATGTTATGTTTCAACGTGTTTATTTTTCAATTCGTATTAGTCATCGCT
AT TACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACG
GG GATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAAC
GG GACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTA
CG GTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGAGATCCAC
CA TGTTTGTCTTTCTCGTGCTGCTGCCCCTCGTGAGCAGCCAGTGCGTCAATCTGACAACAA
GG ACCCAGCTGCCCCCCGCCTACACCAACTCCTTCACAAGAGGCGTGTATTACCCCGATAAG
GT CTTCAGATCCAGCGTCCTCCACAGCACCCAAGATTTGTTTCTGCCTTTCTTCAGCAACGT
GA CATGGTTCCACGCCATTCATGTCAGCGGCACAAACGGCACAAAGAGGTTTGACAACCCCG
TG CTCCCCTTCAACGACGGCGTGTACTTCGCCAGCACAGAGAAATCCAATATCATTAGGGGC
TG GATCTTCGGCACAACACTGGATTCCAAGACCCAGTCTCTGCTCATTGTGAATAACGCCAC
CA ACGTGGTGATTAAGGTCTGTGAGTTTCAGTTCTGCAACGACCCCTTTCTGGGAGTCTACT
AC CACAAGAATAATAAGAGCTGGATGGAGTCCGAGTTTAGGGTGTACAGCTCCGCCAACAAC
TG TACCTTCGAATACGTGTCCCAGCCTTTCCTCATGGATCTGGAGGGCAAGCAAGGCAATTT
CA AAAATCTGAGAGAGTTCGTGTTCAAAAACATTGATGGATACTTCAAAATCTACAGCAAGC
AT ACCCCCATTAATCTGGTGAGGGATCTGCCCCAAGGATTCTCCGCTCTGGAACCTCTGGTG
GA TCTGCCCATTGGCATTAACATCACAAGATTCCAGACCCTCCTCGCCCTCCATAGATCCTA
TC TGACCCCCGGCGACTCCTCCAGCGGATGGACAGCCGGAGCTGCCGCCTACTACGTGGGCT
AT CTGCAGCCAAGAACCTTTCTGCTGAAGTACAACGAGAACGGCACCATCACAGACGCTGTC
GA TTGCGCTCTCGACCCTCTGAGCGAGACCAAATGCACACTGAAGAGCTTCACCGTGGAAAA
GG GCATCTATCAGACCAGCAACTTCAGAGTGCAGCCTACCGAGAGCATTGTGAGGTTTCCCA
AC ATCACCAATCTGTGTCCTTTCGGCGAGGTCTTTAATGCCACAAGGTTCGCTTCCGTGTAT
GC TTGGAATAGGAAGAGGATCAGCAATTGCGTCGCCGACTATTCCGTCCTCTATAACAGCGC
CT CCTTCTCCACCTTCAAATGTTATGGCGTGTCCCCCACCAAGCTCAACGACCTCTGCTTCA
CC AATGTGTACGCTGACTCCTTCGTCATTAGGGGCGACGAGGTGAGGCAAATTGCCCCCGGC
CA GACCGGCAAGATTGCTGATTACAACTACAAACTGCCCGACGATTTTACCGGCTGCGTGAT
CG CTTGGAACTCCAACAATCTGGACTCCAAAGTGGGCGGAAACTACAATTACCTCTACAGAC
TC TTTAGAAAAAGCAATCTGAAGCCCTTCGAGAGAGACATCTCCACCGAAATCTACCAAGCC
GG AAGCACACCTTGCAATGGCGTCGAGGGATTTAACTGCTACTTCCCTCTGCAGAGCTACGG
CT TTCAACCTACCAACGGCGTCGGATATCAACCCTATAGGGTGGTCGTGCTGAGCTTTGAAC
TG CTGCATGCTCCCGCCACCGTCTGCGGACCTAAGAAGAGCACCAATCTCGTCAAAAACAAG
TG CGTGAACTTCAACTTCAATGGACTGACCGGCACCGGCGTGCTGACCGAGAGCAATAAGAA
GT TTCTGCCCTTCCAGCAGTTCGGAAGGGATATTGCCGATACCACAGATGCTGTGAGGGACC
CC CAAACCCTCGAGATTCTGGATATCACCCCTTGCAGCTTCGGAGGAGTGTCCGTGATCACC
CC CGGAACAAACACCTCCAATCAAGTGGCTGTGCTGTACCAAGACGTGAACTGCACAGAAGT
CC CCGTGGCCATCCATGCCGACCAGCTGACCCCTACATGGAGAGTGTACTCCACCGGCAGCA
AT GTGTTCCAGACAAGAGCCGGATGCCTCATTGGAGCTGAACACGTCAACAACAGCTACGAG
TG CGACATTCCCATCGGCGCCGGCATTTGTGCCTCCTATCAGACCCAGACCAACAGCCCAAG
AA GGGCTAGAAGCGTCGCTTCCCAATCCATCATTGCCTACACCATGTCTCTGGGAGCCGAAA
AC TCCGTCGCCTACTCCAACAATAGCATCGCCATCCCCACCAATTTTACCATCTCCGTGACC
AC AGAGATTCTGCCCGTGTCCATGACAAAGACATCCGTGGACTGCACCATGTACATCTGTGG
CG ACAGCACCGAGTGTAGCAATCTGCTGCTGCAATATGGCAGCTTCTGCACCCAGCTGAACA
GA GCCCTCACCGGCATCGCCGTCGAACAAGACAAGAACACCCAAGAGGTGTTCGCCCAAGTG
AA GCAAATCTACAAGACCCCCCCTATCAAAGATTTCGGAGGATTCAACTTTAGCCAGATTCT
GC CCGATCCTAGCAAGCCTTCCAAGAGGAGCTTCATCGAGGATCTGCTGTTTAATAAGGTGA
CA CTGGCCGACGCTGGCTTCATTAAACAGTACGGCGATTGTCTGGGCGACATCGCTGCTAGG
GA TCTGATCTGCGCTCAGAAGTTCAACGGACTGACAGTCCTCCCTCCTCTGCTGACCGACGA
GA TGATCGCTCAGTATACCAGCGCTCTGCTGGCTGGAACCATTACCAGCGGCTGGACATTCG
GC GCTGGAGCCGCCCTCCAAATTCCCTTTGCCATGCAGATGGCCTATAGATTCAACGGCATT
GG CGTCACCCAAAATGTGCTGTATGAAAATCAGAAGCTGATTGCTAACCAATTCAATAGCGC
CA TTGGCAAGATCCAAGACTCTCTGAGCTCCACAGCCAGCGCCCTCGGAAAGCTGCAAGACG
TG GTGAATCAAAACGCCCAAGCTCTGAACACACTGGTGAAACAGCTCAGCAGCAACTTTGGA
GC CATCAGCAGCGTGCTCAATGATATCCTCTCTAGGCTGGACAAAGTGGAGGCCGAAGTCCA
GA TCGATAGACTCATCACCGGCAGACTCCAATCTCTGCAGACATACGTCACCCAACAGCTCA
TT AGAGCTGCCGAAATCAGAGCCTCCGCCAATCTGGCCGCCACCAAGATGTCCGAGTGCGTG
CT GGGACAGAGCAAGAGAGTGGACTTCTGTGGCAAGGGATACCATCTGATGAGCTTCCCCCA
GA GCGCTCCCCATGGAGTGGTCTTTCTGCATGTCACATACGTGCCCGCCCAAGAGAAGAACT
TC ACCACCGCTCCCGCCATTTGCCACGATGGAAAGGCCCACTTTCCCAGAGAAGGAGTGTTC
GT GAGCAACGGCACACACTGGTTTGTCACCCAGAGAAATTTTTACGAGCCCCAGATTATCAC
CA CCGACAACACCTTCGTGTCCGGAAACTGCGATGTCGTGATTGGCATCGTGAACAACACAG
TC TACGACCCTCTGCAGCCCGAACTCGACAGCTTCAAGGAAGAGCTGGACAAGTACTTCAAG
AA TCACACATCCCCCGACGTGGATCTGGGCGACATTAGCGGCATTAATGCCTCCGTCGTCAA
CA TTCAGAAGGAGATTGATAGACTGAATGAAGTCGCCAAGAACCTCAATGAGTCTCTGATTG
AT CTGCAAGAGCTGGGCAAGTACGAGCAATACATCAAATGGCCTTGGTACATCTGGCTGGGA
TT CATCGCTGGACTCATCGCCATCGTGATGGTCACCATTATGCTGTGTTGCATGACCAGCTG
CT GCAGCTGTCTGAAGGGCTGCTGCAGCTGCGGAAGCTGCTGCAAGTTTGACGAAGACGACT
CC GAGCCCGTGCTGAAGGGCGTCAAGCTGCATTATACATAAACTAGTGCTGGAATTCGCCCT
TA TAGAGTGCTGGAATTCGCCCTTATAGAGTGCTGGAATTCGCCCTTATATCTAGTAACGGC
CG CCAGTGTGCTGGAATTCGCCCTTATAACTTCGTATAGCATACATTATACGAAGTTATTGT
TG ACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACAAGGTGAGGAACTAAA
CC ATGGCCAAGTTGACCAGTGCCGTTCCGGTGCTCACCGCGCGCGACGTCGCCGGAGCGGTC
GA GTTCTGGACCGACCGGCTCGGGTTCTCCCGGGACTTCGTGGAGGACGACTTCGCCGGTGT
GG TCCGGGACGACGTGACCCTGTTCATCAGCGCGGTCCAGGACCAGGTGGTGCCGGACAACA
CC CTGGCCTGGGTGTGGGTGCGCGGCCTGGACGAGCTGTACGCCGAGTGGTCGGAGGTCGTG
TC CACGAACTTCCGGGACGCCTCCGGGCCGGCCATGACCGAGATCGGCGAGCAGCCGTGGGG
GC GGGAGTTCGCCCTGCGCGACCCGGCCGGCAACTGCGTGCACTTCGTGGCCGAGGAGCAGG
AC TGAATAACTTCGTATAGCATACATTATACGAAGTTATAAGGGCGAATTCTGCAGATATCC
AT CCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTT
GT TGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTT
CA CAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTAT
CT TAACAACGTGTTTATTTTTCAATTGCAGAAAGAATTGCAGAAAATTTCAAGTCATTTTTC
AT TCAGTAGTATAGCCCCACCACCACATAGCTTATACTAATCACCGTACCTTAATCAAACTC
AC AGAACCCTAGTATTCAACCTGCCACCTCCCTCCCAACACACAGAGTACACAGTCCTTTCT
CC CCGGCTGGCCTTAAACAGCATCATATCATGGGTAACAGACATATTCTTAGGTGTTATATT
CC ACACGGTCTCCTGTCGAGCCAAACGCTCATCAGTGATGTTAATAAACTCCCCGGGCAGCT
CG CTTAAGTTCATGTCGCTGTCCAGCTGCTGAGCCACAGGCTGCTGTCCAACTTGCGGTTGC
TC AACGGGCGGCGAAGGAGAAGTCCACGCCTACATGGGGGTAGAGTCATAATCGTGCATCAG
GA TAGGGCGGTGGTGCTGCAGCAGCGCGCGAATAAACTGCTGCCGCCGCCGCTCCGTCCTGC
AG GAATACAACATGGCAGTGGTCTCCTCAGCGATGATTCGCACCGCCCGCAGCATAAGGCGC
CT TGTCCTCCGGGCACAGCAGCGCACCCTGATCTCACTTAAGTCAGCACAGTAACTGCAGCA
CA GTACCACAATATTGTTTAAAATCCCACAGTGCAAGGCGCTGTATCCAAAGCTCATGGCGG
GG ACCACAGAACCCACGTGGCCATCATACCACAAGCGCAGGTAGATTAAGTGGCGACCCCTC
AT AAACACGCTGGACATAAACATTACCTCTTTTGGCATGTTGTAATTCACCACCTCCCGGTA
CC ATATAAACCTCTGATTAAACATGGCGCCATCCACCACCATCCTAAACCAGCTGGCCAAAA
CC TGCCCGCCGGCTATGCACTGCAGGGAACCGGGACTGGAACAATGACAGTGGAGAGCCCAG
GA CTCGTAACCATGGATCATCATGCTCGTCATGATATCAATGTTGGCACAACACAGGCACAC
GT GCATACACTTCCTCAGGATTACAAGCTCCTCCCGCGTCAGAACCATATCCCAGGGAACAA
CC CATTCCTGAATCAGCGTAAATCCCACACTGCAGGGAAGACCTCGCACGTAACTCACGTTG
TG CATTGTCAAAGTGTTACATTCGGGCAGCAGCGGATGATCCTCCAGTATGGTAGCGCGTGT
CT CTGTCTCAAAAGGAGGTAGGCGATCCCTACTGTACGGAGTGCGCCGAGACAACCGAGATC
GT GTTGGTCGTAGTGTCATGCCAAATGGAACGCCGGACGTAGTCATATTTCCTGAAGCAAAA
CC AGGTGCGGGCGTGACAAACAGATCTGCGTCTCCGGTCTCGTCGCTTAGCTCGCTCTGTGT
AG TAGTTGTAGTATATCCACTCTCTCAAAGCATCCAGGCGCCCCCTGGCTTCGGGTTCTATG
TA AACTCCTTCATGCGCCGCTGCCCTGATAACATCCACCACCGCAGAATAAGCCACACCCAG
CC AACCTACACATTCGTTCTGCGAGTCACACACGGGAGGAGCGGGAAGAGCTGGAAGAACCA
TG TTTTTTTTTTTTATTCCAAAAGATTATCCAAAACCTCAAAATGAAGATCTATTAAGTGAA
CG CGCTCCCCTCCGGTGGCGTGGTCAAACTCTACAGCCAAAGAACAGATAATGGCATTTGTA
AG ATGTTGCACAATGGCTTCCAAAAGGCAAACTGCCCTCACGTCCAAGTGGACGTAAAGGCT
AA ACCCTTCANGGTGAATCTCCTCTATAAACATTCCAGCACCTTCAACCATGCCCAAATAAT
TT TCATCTCGCCACCTTATCAATATGTCTCTAAGCAAATCCCGAATATTAAGTCCGGCCATT
GT AAAAATCTGCTCCAGAGCGCCCTCCACCTTCAGCCTCAAGCAGCGAATCATGATTGCAAA
AA TTCAGGTTCCTCACAGACCTGTATAAGATTCAAAAGCGGAACATTAACAAAAATACCGCG
AT CCCGTAGGTCCCTTCGCAGGGCCAGCTGAACATAATCGTGCAGGTCTGCACGGACCAGCG
CG GCCACTTCCCCGCCAGGAACCATGACAAAAGAACCCACACTGATTATGACACGCATACTC
GG AGCTATGCTAACCAGCGTAGCCCCGATGTAAGCTTGTTGCATGGGCGGCGATATAAAATG
CA AGGTACTGCTCAAAAAATCAGGCAAAGCCTCGCGCAAAAAAGCAAGCACATCGTAGTCAT
GC TCATGCAGATAAAGGCAGGTAAGTTCCGGAACCACCACAGAAAAAGACACCATTTTTCTC
TC AAACATGTCTGCGGGTTCCTGCATAAACACAAAATAAAATAACAAAAAAAAAAAAACATT
TA AACATTAGAAGCCTGTCTTACAACAGGAAAAACAACCCTTATAAGCATAAGACGGACTAC
GG CCATGCCGGCGTGACCGTAAAAAAACTGGTCACCGTGATTAAAAAGCACCACCGACAGTT
CC TCGGTCATGTCCGGAGTCATAATGTAAGACTCGGTAAACACATCAGGTTGGTTAACATCG
GT CAGTGCTAAAAAGCGACCGAAATAGCCCGGGGGAATACATACCCGCAGGCGTAGAGACAA
CA TTACAGCCCCCATAGGAGGTATAACAAAATTAATAGGAGAGAAAAACACATAAACCCCTG
AA AAACCCTCCTGCCCCTAGGCAAAATAGCACCCTCCCGCTCCAGAACAACATACAGCGCTT
CC ACAGCGGCAGCCATAACAGTCAGCCTTACCAGTAAAAAAACCTATTAAAAAACACCACTC
GA CACGGCACCAGCTCAATCAGTCACAGTGTAAAAAGGGCCAAGTACAGAGCGAGTATATAT
AG GACTAAAAAATGACGTAACGGTTAAAGTCCACAAAAACCACCCAGAAAACCGCACGCGAA
CC TACGCCCAGAAACGAAAGCCAAAAAACCCACAACTTCCTCAAATCTTCACTTCCGTTTTC
CC ACGATACGTCACTTCCCATTTTAAAAAAAAACTACAATTCCCAATACATGCAAGTTACTC
CG CCCTAAAACCTACGTCACCCGCCCCGTTCCCACGCCCCGCGCCACGTCACAAACTCCACC
CC CTCATTATCATATTGGCTTCAATCCAAAATAAGGTATATTATTGATGATGGCGAT OTHER EMBODIMENTS It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.